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1. INTRODUCTION AND THE PURPOSE OF THE DISSERTATION 
 
Pluripotent stem cells 
Stem cell pluripotency.  By definition, stem cells have the capacity for self renewal 
and differentiation toward one or more mature cell types.(1-3)  Thus, virtually any cell type in 
the body can be derived from pluripotent stem cells.  Therefore, pluripotent stem cells have 
immense potential for various applications.   
In general, the pluripotency of stem cell lines is tested by analyzing the expression of 
pluripotency markers and their ability to differentiate into more mature cell types.  Pluripotent 
stem cells can differentiate into derivatives of all three embryonic germ layers.(4)  As such, 
they have an immense potential for various applications in clinical practice and industry like 
generation of human cardiomyocytes for transplantation therapy of infarcted myocardium or 
for in vitro pharmacological testing.(5, 6)  Human embryonic stem cells (hESCs) have been 
the most widely studied pluripotent stem cells, but their use is hampered by ethical issues and 
immune rejection of allogenic graft.(2, 7)  However, they are considered as gold standard in 
stem cell biology due to their natural pluripotency.  Recently, generation of human induced 
pluripotent stem cells (hiPSCs) by introduction of pluripotency factors into skin fibroblasts 
resolved these two issues.(8)  Similar to hESCs, hiPSCs exhibit indefinite self-renewal and 
the ability to differentiate into virtually any cell type in human body.(3)  Hence, hiPSCs 
provide the possibility of performing cell replacement therapy with patient-matched cells, 
circumventing severe complications of life-long immunosupression therapy that inevitably 
follows allogenic grafts.(9)  
Two hESC, H1 and H9, and two hiPSC lines, C2a and C6a, used here were previously 
validated for their pluripotency.(10-12)  H1 and H9 lines are morphologically similar to 
rhesus monkey ESC and have normal karyotypes.  They also express high telomerase activity 
which indicates their immortality.  H1 and H9 cells also express characteristic markers 
specific for undifferentiated cells, i.e. alkaline phosphatase, SSEA3, SSEA4, TRA-1-60 and 
TRA-1-81.(11)  Teratomas are formed when these cells are transplanted to 
immunocompromised, SCID-beige mice.  Teratomas are tumors formed from more than one 
germ layer indicating pluripotency of these cells.  As pluripotent stem cells, H1 and H9 can be 
differentiated into all three germs layers and their derivatives, such as cardiomyocytes, 
neurons, hepatocytes and other cell types.(11, 12) 
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C2a and C6a hiPSC lines were generated in the laboratory of Dr. S Duncan, MCW by 
transducing human foreskin fibroblasts with lentiviruses encoding OCT4 (octamer-binding 
transcription factor 4; also known as POU5F1 (POU class 5 homeobox 1)), SOX2 (sex 
determining region Y-box 2), NANOG (Nanog homeobox) and LIN28 (lin-28 homolog).(10)  
These cells are morphologically similar to ESCs and express pluripotency markers OCT4 and 
SSEA4 and exhibit alkaline phosphatase activity.  They also form teratomas and display 
normal karotypes.  Cells can be differentiated into derivatives of all three germ layers, 
including neuronal tissue, sebaceous tissue, columnar epithelium, gut-like epithelium, striated 
muscle, blood cells, adipose tissue, cartilage and immature bone.  DNA fingerprinting showed 
that lines completely match human foreskin fibroblasts that were used for 
reprogramming.(10) 
hiPSCs.  Until recently, lines of pluripotent cells derived from human embryos, hESCs 
were the most widely investigated.  However, the potential for therapeutic use of ESCs is 
hampered by ethical issues, immune rejection of allogeneic grafts, and oncogenic risk.  The 
first two of these issues may have been recently resolved by the ability to generate iPSCs 
from human dermal fibroblasts, via transduction of pluripotency factors encoded in retroviral 
vectors.(8, 9)  iPSCs provide the possibility of performing cell replacement therapy with 
patient-matched cells.  In addition, disease-matched iPSC-lines will enable studies to 
determine the influence of genetic background on the differentiation of specific cell types, 
which has already been accomplished in the instance of a congenital heart defect that causes 
hypertrophic cardiomyopathy.(13) 
hiPSCs are probably the fastest developing field in stem cell research and among the 
most promising areas of science, translational research and clinical medicine.(14, 15)  Ever 
since the first description of the iPS cells in 2006, the field rapidly grew and it is on a verge to 
become one of the driving forces of translational research.(6)  hiPSCs also have the immense 
potential in regenerative medicine, circumventing considerable problems that accompany the 
use of hESCs.(15)  However, our knowledge about the applicability of hiPSCs for these 
purposes is limited and there is still uncertainty whether hiPSCs have comparable potential in 
cardiomyogenesis as hESCs.  Takahashi and Yamanaka successfully derived iPSCs from 
adult mouse fibroblasts through ectopic coexpression of four genes OCT4, SOX2, KLF4 
(Kruppel-like factor 4 (gut)) and c-MYC (c-avian myelocytomatosis viral oncogene 
homolog).(16)  Very soon human fibroblasts were also converted into pluripotent stem cells 
followed by successful reprogramming of variety of other cells including adipose stem cells, 
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neural stem cells, stomach cells liver cells, melanocytes, keratinocytes and other cell 
types.(15, 17)  Also, it was demonstrated that other combinations of stemness factors can be 
used for successful reprogramming, like OCT4, SOX2, LIN28, NANOG or OCT4, SOX2, 
KLF4 without c-MYC.  At the beginning, reprogramming required transduction of cells using 
retroviral vectors which introduced potential side effects like the induction of inflammation or 
caused cell rejection after transplantation.  Moreover, insertion of viral genome at unknown 
locations can generate oncogenic response.(15) 
Recently, it was shown in several studies that iPSCs can be generated by using non-
integrating viruses or without using viral vectors at all.(15)  Variety of growth factors and 
chemical compounds have been found to improve the efficiency of iPSC induction, like 5-
azacytidine and valproic acid.  There is a series of molecular hallmarks which distinguish 
fully reprogrammed iPSCs from those only partially reprogrammed.  They include OCT4, 
SOX2, NANOG, telomerase gene and SSEA1.(15)  Genome-wide epigenetic reprogramming 
is essential for generating cells which are fully reprogrammed and thus comparable to ESCs. 
iPSCs which originate from different cell sources show similar gene expression patterns in the 
pluripotent state, but they also more readily differentiate toward the tissue of origin.  
Therefore, the memory could be epigenetic.  The evaluation of methylation at the promoters 
of the pluripotency genes and of the genes responsible for driving differentiation is a way of 
measuring the success of reprogramming.(15) 
Ethical issues and regulatory acts.  Experiments carried out in this thesis are 
performed in accordance with European Science Foundation and International Society for 
Stem Cell Research issued rules and guidelines to ensure transparent, ethical and responsible 
research (please see link http://www.isscr.org/docs/default-source/hesc-
guidelines/isscrhescguidelines2006.pdf).  The major ethical concern of this thesis is the use of 
human embryonic stem cells (hESCs).  However, this research is in agreement with the 
widely accepted guidelines of hESCs research, i.e. only commercially available hESCs were 
utilized.  We did not generate new lines of hESCs or in any other way use human embryos or 
their parts.  We did not use pre-implantation human embryos, do any transplantations into 
living human subjects or generate chimeric animals.  Each research project using hESCs 
should take in consideration potential scientific questions, examine the current ethical 
concerns and estimate whether this research would advance towards clinical application.   
European Science Foundation (ESF) published in 2002 a Science Policy Briefing 
(SPB) entitled Human Stem Cell Research: Scientific Uncertainties and Ethical Dilemmas.  
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Since then there have been many significant advances in this field of research, therefore the 
European Medical Research Councils (EMRC) at the ESF established a High-Level Expert 
Group to reflect the rapidly changing scope of  the field.  These members made specific 
recommendations ensuring that the research is conducted in accordance with accepted 
principles of research ethics.  Furthermore, the International Society for Stem Cell Research 
(ISSCR) has formed the Task Force which has formulated the Guidelines for the Conduct of 
Human Embryonic Stem Cell Research that articulate ethical principles and rules of behavior 
for the performance of human stem cell research.  ISSCR calls for due consideration and 
appropriate oversight of human stem cell research to ensure transparent, ethical and 
responsible performance of scientific experiments.  To ensure that stem cell research is 
proceeding with due consideration ISSCR proposes specific categories of research, which are 
following:  
1. Category 1: Experiments that are permissible after review under existing mandates and 
by existing local committees, and are determined to be exempt from full Stem Cell 
Research Oversight (SCRO) review.  These will include experiments with pre-existing 
hESC lines that are confined to cell culture or involve routine and standard research 
practice, such as assays of teratoma formation in immune-deficient mice. 
2. Category 2: Forms of research that is permissible only after additional and 
comprehensive review by a specialized mechanism or body established to address the 
issues pertinent to stem cell research.   
3. Category 3: Research that should not be pursued at this time because of broad 
international consensus that such experiments lack a compelling scientific rationale or 
raise strong ethical concerns. 
Experiments proposed in the present thesis include only the use of human embryonic 
stem cells that are confined to cell culture, can be commercially purchased and involve 
routine and standard procedures, such as in vitro differentiation into derivatives of embryonic 
layers, immunocytochemistry or PCR experiments.  These experiments are determined by 
Category 1 from ISSCR's Guidelines for the Conduct of Human Embryonic Stem Cell 
Research.  We are not performing any of the experiments described in categories 2 or 3 which 
include procedures like derivation of new human pluripotent cell lines, use of pre-
implantation human embryos, transplantations into living human subjects or generation of 
chimeric animals.   
Importance of Stem Cell Biology.  Stem cell research has an important role in applied 
science, including: 1) disease modeling and studying pathogenesis of human diseases; 2) 
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embryonic development and tumor pathogenesis and 3) basic studies of regeneration of 
tissues and organs. 
In his recent article, Dr. Francis S. Collins, the Director of National Institutes of 
Health pointed out that the current process of development of new drugs, which is based on 
translation findings from animal models to clinical practice, is costly, takes too much time and 
has a high rate of failure.(6)  It takes 13 years to develop one drug with the cost of more than 
a billion dollars and the failure rate of 95%.  This process is inefficient in large part since 
results obtained on animals do not reliably reflect the nature of human disease and drug safety 
in humans.  He identified the use of cells derived from hESCs and hiPSCs as a promising 
strategy that may circumvent these problems and serve as a complementary experimental 
model.  The use of human stem cell-based models is called “clinical trial in a dish”.  In this 
dissertation we tested cardiomyogenesis in hESCs and hiPSCs and validate it by testing their 
potential to yield cells with a phenotype of functional cardiac cell, i.e. cardiomyocytes that 
can rhythmically contract and express organized contractile machinery-sarcomeres.  This 
characterization was crucial for our ability to understand the potential of hiPSCs to be used as 
pharmacological model of human cells. 
An important aspect of stem cell research includes cancer stem cells.(18)  In the past 
several years, impressive studies showed existence of cancer stem cells as a specific 
subpopulation of tumor cells, which play the key role in cancer development, metastasizing 
and resistance to chemo- and radiotherapy.(18)  Furthermore, studies show that tumor cells 
exhibit characteristics that are genetically-driven, not just by random mutation, but with 
activation of complex programmed processes that in many aspects resemble those in normal 
stem cells, suggesting activation of stem cell genes in cancer stem cells.(19)  Therefore, 
cancer stem cells open exciting new horizons in studying tumor development and designing 
effective targeted therapies. 
Probably the most groundbreaking aspect of human stem cell research is their 
application for regenerative medicine.  With the increase in the number of patients suffering 
from chronic diseases and increasing ageing of population, the requirement for transplantation 
of organs is in constant rise, while the number of suitable organ/tissue donors is insufficient.  
For many terminal organ insufficiencies (e.g. heart and liver failure) transplantation is the 
only therapy.  Potential applications of stem-cell-based therapy that are vigorously 
investigated include cardiac muscle repair following myocardial infarction, treatment of 
neurodegenerative disorders like Parkinson's disease and the replacement of the non-
functioning cells of the Langerhans islets in diabetes mellitus.  Mouse liver can be regenerated 
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with hiPSCs.(10)  Clinical trials have been initiated to examine the potential of using stem 
cell for regeneration of various organs.  
The loss of terminally differentiated cardiomyocytes is replaced by proliferation of 
connective tissue that diminishes contractile function leading to heart failure.  The only true 
and efficient therapy of infarcted myocardium would be replacing cardiomyocytes with new 
cardiomyocytes.  Thus, considerable research efforts and funds are aimed at testing the 
potential of stem cells in regeneration of dysfunctional heart.  However, at present, this 
approach is hampered by poor engraftment of transplanted cells.(20)  This dissertation may 
advance the field of transplantation medicine since it may offer new possibility to increase the 
efficiency of stem cell engraftment by protecting them with anesthetic preconditioning (APC).  
Ethical issues and the immune rejection of allogenic transplant hamper the transplantation 
potential of hESCs.  On the other hand, hiPSCs offer promising alternative since they 
originate from patient’s own cells, like fibroblasts, and thereby are not burdened with ethical 
issues nor immune reaction.(8) 
Shinya Yamanaka is a Nobel Prize laureate for 2012 for the discovery of iPSCs that 
was published in the Cell in 2006.(16)  In 2013, nearly 20,000 manuscripts related to stem 
cells have been published in PubMed database.  The ClinicalTrials.gov website has more than 
4,500 listed clinical trials related to stem cells.  The importance of stem cells research and 
organ recovery is recognized by world’s leading biomedical institutions that have established 
centers or institutes for stem cells and regenerative medicine.  
 
The Development of the Heart and Cardiomyocyte Differentiation 
Among other possible implementations pluripotent stem cells have contributed to 
developmental biology research through generation of an in vitro model which enables 
studying normal and pathological development of an early mouse and human embryos.(21-
23)  Several studies have shown that mouse ESCs recapitulate important early cardiogenic 
events in vitro.(24)  Upon the derivation of the human ESCs it has been shown that they can 
give rise to the functional cardiomyocytes.(11, 12) 
Circulatory system, comprised of a heart, blood cells and blood vessels is the first 
functional unit in the developing embryo providing nourishment to the growing organism. In 
the amniote vertebrates, the cells which will later form the atrial and ventricular musculature, 
the Purkinje conducting fibres and the endothelial cells of the heart originate in the early 
primitive streak, migrate through it and form the cardiogenic mesoderm at each side of the 
Hensens node.(25, 26)  Induction of the specification of the cardiac precursor cells comes 
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from the endoderm adjacent to the heart and includes BMP and FGF signaling pathways.(24, 
25)  Heart precursor cells are specified by the overlap of Wnt (wingless-type MMTV 
integration site family) antagonists and BMPs.(24)  Upon and in parallel with specification 
heart precursor cells migrate towards the lateral walls of the anterior gut tube. The signals for 
this migration come from the foregut endoderm. Upon the formation of the foregut by inward 
folding of the splanchnic mesoderm the two cardiac tubes are brought together.(25, 27)  
While migrating, the cells of the cardiogenic mesoderm are instructed by the BMP signals to 
synthesize the NKX2.5 (NK2 homeobox 5) transcription factor which acts as a transcriptional 
activator of atrial natriuretic factor in cooperation with GATA4 (GATA binding protein 4) 
and probably other members of GATA and MEF2 (myocyte enhancer factor 2) families.(24, 
27)  These transcription factors activate the expression of cardiac specific genes which 
encodes proteins such as cardiac actin, titin, atrial natriuretic factor and myosin heavy 
chains.(24)  The heart cells differentiate in the two separate heart primordia migrating toward 
each other.  Their merging is forming an epithelium which will give rise to myocardium.  The 
fusion of the two heart primordia occurs at about 3 weeks in human gestation, but the 
pulsations of the heart begin before the fusion is completed.  The pulsations can occur upon 
the development of functional sodium-calcium exchange pump in the muscle cell membrane.  
In 5-week human embryo the heart is composed of one atrium and one ventricle.  Looping of 
the heart is designated within the heart primordium while the NKX2.5 regulates the HAND1 
and HAND2 transcription factors.  HAND1 is restricted to the future left ventricule and 
HAND2 to the right as the looping progresses.(24, 26, 27) 
It has been demonstrated that cardiac precursor cells are present in the pre-streak 
embryos, before the process of gastrulation in which the three germ layers are formed.(24-26)  
Upon the formation of primitive streak a group of epiblast cells undergoes epithelial-to-
mesenchymal transition and formes the transient layer - the mesendoderm.(27)  The 
segregation of endoderm and mesoderm from mesendoderm is a key event in defining the 
cardiac lineages.  It has been shown that GATA factors 4, 5 and 6 play an immportant role in 
specification of both endoderm and mesoderm.(27)  Furthermore, it has been shown both in 
embryos and hESCs that members of the TGFβ family (transforming growth factor beta) 
Nodal and activin are acting in accordance with Wnt/b-catenin pathway in defining the 
mesendoderm formation.(24)  Another member of TGFβ family, BMP2 which is secreted by 
both visceral and pharyngeal endoderm is responsible for further specification of 
mesendoderm into cardiac specific direction.(27)  Transcription factor OCT4 enables normal 
cardiogenesis through its target gene SOX17 required for specification of cardiac mesoderm.  
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Mesendodermal transient cell status depends on an equilibrium of Nodal/BMP and Wnt 
pathways and it is crucial in determination of cardiac cell fate.  The anterior part of the 
primitive streak contains precursors of endocardium, myocardium and epicardium.  These 
mesodermal cells express GATA 4,5 and 6, HAND1 and 2, WT1 (Wilms tumor 1) and 
NKX2.5.(24, 25, 27)  The signals which induce the migration of cardiogenic mesodermal 
cells remain to be investigated but it is suggested that the transcription factor MESP1 has a 
role in this process.  It has been shown that MESP1 is immportant for epithelial-to-
mesenchymal transition and for delamination and migration of cardiac progenitors from the 
primitive streak.(27)  Several cell lineages originate from the lateral mesoderm including 
haematopoietic and cardiac cell lineages.  These two lineages are segregated early during the 
migration of epiblast through the primitive streak.  A study done by the Duncan′s laboratory 
shows an essential role of GATA 4 and 6 in the cardiac transcriptional pathway.(28)  A recent 
study also shows the immportant role of FGFs in favouring the cardiac mesoderm at the 
expense of hematopoietic one.(24)  In cardiogenic mesoderm the transcription factor NKX2.5 
repress the haemangiopoietic program in part by repressing GATA1 which further 
antagonises the cardiac and hematopoietic cell lineages.  Next, a population of cardiac 
progenitors migrates into the heart field with subsequent differentiation into either endocardial 
or myocardial cells.(24, 26, 27)  Several genetic lineage tracing studies suggest that 
endocardial and myocardial cells share a common FLK1+ progenitor.(29)  In vitro studies 
utilizing ESCs have suggested the presence of two cardiac cell lineages, first (ISL1-,TBX5+) 
and second (ISL1+, TBX1+, RALDH2+, FOXH1+) which can be segregated from the 
MESP1+ ESC-derived mesodermal cells.(24) 
 
Disease Modeling Based on Stem Cell Differentiation 
iPSCs are generated by reprogramming fibroblasts or other mature, differentiated 
cells.(8)  Reprogramming enables cells to return to the state of pluripotency and subsequently 
to be re-differentiated into cardiac, neuronal, hepatic or other lineages.(10, 30, 31)  
Fibroblasts can be conveniently isolated from small (several millimeter) skin samples from 
the patient.  Reprogramming is based on various techniques of delivery of pluripotency 
factors or genes.  Cells differentiated from reprogrammed fibroblasts maintain original 
genetic material (nuclear and mitochondrial DNA) of the patient and cellular characteristics 
(phenotype)-driven by the genotype.  An increasing number of publications in high-impact 
journals show that iPSCs obtained from a skin sample of a patient with genetically-driven 
disease can be differentiated into cardiomyocytes, neurons or other cell types that exhibit 
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characteristics of that disease (Figure 1).(32, 33)  Such proof-of-principle studies demonstrate 
that human iPSCs can be used for studying pathogenesis of human disease and development 
of new drugs and other therapeutic interventions using human experimental models instead of 
animal that are not completely compatible to human genetically-driven diseases.  For 
example, human iPSC-cardiomyocytes were derived from patients with various arrhythmias 
with long QT syndromes or catecholaminergic polymorphic ventricular tachycardia, human 
iPSC-neurons were generated from patients with Parkinson’s disease and Best disease.(33-36)  
iPSCs were also reprogrammed from mice with lysosomal storage diseases.(33, 37)  All these 
models exhibit characteristic electrophysiological, metabolic and other characteristic 
phenotypes.  Other diseases can also be modeled with iPSC approach, including neurons for 
Alzheimer’s disease or hepatocytes for hereditary metabolic diseases of the liver.(31, 38)  
iPSCs are also used for in vitro studies of human embryonic development, which is a new 
powerful tool in efforts to understand developmental disorders.  The latest and exciting 
breakthrough is a study that demonstrates in vitro genesis of “cerebral organoids”, a 3D 
culture system that recapitulates cortical development with formation of discrete brain 
regions, including organized mature cortical neuron subtypes.(39)  Authors also demonstrated 
successful modeling of microcephaly using the same model.   
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Figure 1. Disease modeling using patient-derived hiPSCs.  Human iPSCs can be generated 
by introducing pluripotency factors into fibroblasts.  Obtained iPSC colonies can be further 
differentiated into cardiomyocytes or other cell types and subsequently used for experiments.  
The patient’s original genetic material is preserved from isolated fibroblasts, iPSCs down to 
iPSC-cardiomyocytes.  Therefore, the phenotype of such iPSC-cardiomyocytes is in part 
driven by patient’s genetic background.  This allows examination of these genotype-driven 
characteristics in strictly controlled experimental environment.  Moreover, interactions among 
environmental and genetic factors can be examined.  Such approach is particularly useful for 
experiments with human cardiomyocytes since these cells are almost unavailable for 
experimental purposes. 
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Myocardial Infarction and Ischemia-Reperfusion Injury 
Cessation of blood flow through coronary arteries (ischemia) inevitable causes 
cardiomyocyte death, i.e. myocardial infarction, unless the blood flow is reestablished.  
However, it has been well documented that reperfusion following relatively short ischemia 
induces more cell death than the ischemia itself.(40, 41)  This seeming paradox has been 
described as reperfusion injury, which encompasses multiple noxious stimuli.(41-43)  
Myocardial infarction may lead to acute and chronic heart failure and death.  Life threatening 
complications include various arrhythmias, like ventricular fibrillation, rupture of papillary 
muscle with mitral valve insufficiency, ventricular aneurism and wall rupture causing cardiac 
tamponade, and cardiogenic shock due to reduced contractility.  Death of cardiomyocytes 
during ischemia-reperfusion is a consequence of complex intracellular processes that can be 
attenuated by various interventions, including preconditioning.(44, 45) 
Reactive oxygen species.  The burst of reactive oxygen species (ROS) production 
during the first couple of minutes of reperfusion is considered as the most important stressor 
of the reperfusion.(46, 47)  Attenuation of this ROS burst by different strategies has led to 
improved cardiomyocyte survival in various in vitro and in vivo experimental models.(48, 49)  
For example, superoxide dismutase (SOD) overexpression reduces infarct size in transgenic 
mice.(50)  Different preconditioning strategies attenuate excessive ROS production during 
reperfusion in vivo and during simulated reperfusion in vitro and thereby protect 
cardiomyocytes.(51, 52)  However, clinical trials attempting to introduce antioxidants during 
coronary reperfusion in humans did not show any protective effects.(53)  A plausible 
explanation for this disappointing result is that the burst of ROS production in reperfusion 
occurred before antioxidants were able to diffuse into cardiac mitochondria, which is the main 
site of ROS production in injured cardiomyocytes.(47) 
ROS can damage numerous cellular molecules and structures, including lipid 
peroxidation, protein oxidation and carbonylation.(54, 55)  Opening of the mitochondrial 
permeability transition pore (mPTP) by ROS is the critical event triggering cell death 
pathways, and protective effects of antioxidants are well correlated with attenuation of mPTP 
opening.(56, 57)  An important source of excessive ROS production during reperfusion are 
inflammatory cells that infiltrate injured myocardium attracted by necrotic cells.(58)  
However, in early reperfusion of the heart, ROS are predominantly produced by postischemic 
cardiomyocytes, which is stimulated by sudden repletion of oxygen and increase in 
mitochondrial membrane potential.(47, 59)  Alterations in the respiratory chain precipitated 
by ischemia in the form of decreased activity of the complex III, lower cytochrome c content 
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and decreased respiration through cytochrome oxidase also contribute to reperfusion ROR 
burst.(60-64)  Other sources of ROS within cardiomyocytes include xanthine oxidase and 
NADPH oxidase.(65) 
The extent of ROS generation during ischemia is controversial.  Although some in 
vitro studies show increase in ROS production during ischemia, these results are questionable 
primarily due to the fact that during ischemia oxygen levels are far too low to provide 
substantial amount of substrate for superoxide generation.(42, 66)  In these experiments 
cardiomyocytes were in contact with atmospheric air, which is not the case in vivo, and which 
could have served as the source of oxygen for ROS generation, probably causing observed 
artifact.(42)  
Calcium.  The burst of ROS production during reperfusion also stimulates 
accumulation of cytosolic calcium by stimulating its release via the ryanodine receptor on the 
sarcoplasmic reticulum.(67-69)  However, intracellular calcium starts to rise also during 
ischemia, when ROS concentration is probably negligible (as discussed above).(70)  A drop in 
intracellular ATP concentration during ischemia is responsible for calcium overload in 
ischemic cardiomyocytes by several different mechanisms.  First, ATP-ases that actively 
pump calcium from the cytoplasm stop working due to low ATP.(42)  This refers to plasma 
membrane calcium ATP-ase (PMCA) and sarcoplasmic/endoplasmic reticulum calcium ATP-
ase (SERCA).  Moreover, a decrease in intracellular pH due to anaerobic lactate production 
activates sodium/hydrogen exchanger that imports sodium into the cell.(71)  This in 
combination with slowing down of sodium/potassium exchanger due to low ATP decreases 
the transmembrane sodium gradient that in turn reverses the action of sodium/calcium 
exchanger, leading to calcium import into the cell.(72)  Last, depolarization of sarcolemma 
facilitates opening of voltage-sensitive L-type calcium channels whose opening leads to 
further calcium inflow.(42, 73)  Calcium-induced calcium release, where calcium stimulates 
its own release from the sarcoplasmic reticulum by the ryanodine receptor exacerbates 
calcium accumulation.(74) 
A rise in cytosolic calcium will facilitate mitochondrial calcium uptake, driven by the 
mitochondrial membrane potential (∆Ψm), via mitochondrial calcium uniporter.(75, 76)  In 
mitochondria, calcium stimulates respiration and thereby can enhance ROS production during 
early reperfusion.(77)  Moreover, calcium and ROS stimulate opening of the mPTP in 
mitochondria which can further stimulate ROS production and contribute to calcium overload 
by releasing intramitochondrial calcium.(78, 79)  Hence, accumulation of calcium and 
excessive ROS production depend on multiple interconnected processes, which can serve as 
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target for cardioprotective strategies. APC may directly attenuate excessive ROS production 
by slightly depolarizing mitochondria, but it may also indirectly attenuate intramitochondrial 
and cytosolic calcium overload by reducing ROS-induced calcium release from the 
sarcoplasmic reticulum.(80)  Decrease in intracellular pH during ischemia has protective 
effects, since protons compete with calcium for the binding site on the mPTP, thereby 
preventing calcium-induced mPTP opening.(81) 
In addition to opening of mPTP, calcium overload will lead to activation of various 
enzymes including endonucleases and proteases, such as calpain that will cleave intracellular 
structural and other proteins contributing to necrotic cell death.(42, 82) 
 
Anesthetic Preconditioning 
In 1986 Murry and colleagues demonstrated that several brief periods of ischemia and 
reperfusion reduced infarct size when dogs were subjected to prolonged ischemia and 
reperfusion.(45)  This has been named ischemic preconditioning.  Later on various other 
agents were shown to induce preconditioning and protect the heart from ischemia and 
reperfusion injury.  Volatile anesthetic, such as isoflurane, sevoflurane and desflurane are 
among those agents and this has been called anesthetic preconditioning (APC).(83)  APC is a 
cardioprotective strategy that increases resistance to ischemia and reperfusion (I/R) by 
eliciting innate protective mechanisms.(83, 84)  Preconditioning protects other organs, as 
well, like brain liver and kidney.(85-87)  Volatile anesthetics may reduce reperfusion injury if 
applied at the onset of reperfusion, which is called anesthetic postconditioning, and it is 
clinically more applicable strategy(88).  Postconditioning recruits RISK (Reperfusion Injury 
salvage Kinases) and SAFE (Survivor Activating Factor Enhancement) pathways.(89)  RISK 
pathway is somewhat similar to preconditioning signaling cascade.  Induction of ischemic 
preconditioning of a limb can also protect the heart and this is called remote 
preconditioning.(90)  A randomized, single-blinded, placebo-controlled prospective study 
demonstrated that combination of isoflurane/sufentanil anesthesia and remote preconditioning 
by intermittent upper arm ischemia reduced serum troponin I in patients undergoing coronary 
artery bypass graft (CABG) surgery.(91)  This study further corroborated clinical value of 
cardioprotection by volatile anesthetics and demonstrated importance of unraveling 
mechanism of cardioprotection and finding optimal protocols for clinical practice. 
General principles of APC.  It is now recognized that preconditioning activates 
endogenous cytoprotective mechanisms in cells rendering them more resistant to ischemia-
reperfusion injury and oxidative stress, which is a hallmark of reperfusion injury.(80, 83)  The 
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signaling phase of preconditioning, including APC, includes signal transduction cascade 
initiated by preconditioning stimulus (brief ischemic episode, application of volatile 
anesthetic or hydrogen peroxide) that results in activation of effectors of preconditioning.(92, 
93)  These effectors remain active even after removal of the anesthetic, i.e. during prolonged 
ischemia and reperfusion, which is called memory phase.(92)  There are two windows of 
protection during memory phase, the first lasting for couple of hours and second starting 12h 
after the stimulus and ending 24-48h later.(94)  The first window of protection is 
characterized by activation of effectors of protection by posttranslational modifications, such 
as phosphorylation or by translocation of crucial regulatory proteins, including translocation 
of protein kinase C to mitochondria.(93)  Some of the identified effectors of protection are 
mitochondrial and sarcolemmal KATP channels.(95-97)  The former depolarizes mitochondria 
and attenuates mitochondrial ROS production and calcium accumulation.(83)  The later 
hyperpolarizes sarcolemma reducing deleterious calcium influx.(83) 
Signal transduction cascade of APC involves several parallel and independent 
pathways.(92)  The important components of this cascade are extracellular signal-regulated 
kinases (ERKs), phosphatidylinositol 3-kinase (PI3-kinase)/protein kinase B (Akt) pathway, 
protein kinase C.  Activation of adenosine receptors (A1 and A3) by released adenosine also 
transmits preconditioning signals.(84, 93)  It has been noticed in clinical work that myocardial 
infarction is smaller in patients who experienced attacks of angina pectoris 2h prior to 
coronary occlusion that in those who did not have prior chest pain.(98)  This is considered as 
clinical correlation of ischemic preconditioning.  Over the past years, the laboratory of Dr. 
Bosnjak has made a substantial progress in understanding fundamental processes responsible 
for the development of cardiac ischemia-reperfusion injury and the protection against it by 
APC.  Mitochondria emerged as central organelles involved in pathological processes during 
ischemia-reperfusion, but also a key site of preconditioning signal and effectors.(80, 83) 
Cardioprotection by volatile anesthetics is now accepted in clinical practice.  Namely, 
the American Cardiology Society and the American Heart Association recommend the use of 
volatile anesthetics due to their cardioprotective properties in surgeries where heart damage 
can be expected.(99)  However, ageing and diabetes mellitus adversely affect the ability of 
APC to exert cardioprotection.(100, 101)  This urges for further research aimed at 
understanding molecular principles of APC and treatments required to restore APC in such 
patients. 
Preconditioning cannot be elicited by intravenous anesthetics, such as barbiturate, 
which is than conveniently used for animal anesthesia in preconditioning studies.  
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Preconditioning protocols include administration of volatile anesthetic either to animals by 
inhalation or to isolated cells by superfusion with solution containing equipotent 
concentration of anesthetics.  Most of the protocols involve application of anesthetics from 10 
to 30 minutes followed by anesthetic washout prior to exposing cells to various forms of 
injury (ischemia-reperfusion, hypoxia-reoxygenation, metabolic inhibition-“reperfusion” or 
oxidative stress by hydrogen peroxide).  The anesthetic washout period is important to 
distinguish preconditioning effects from possible direct protective effects of anesthetics 
(postconditioning).  As liposolubile substances, volatile anesthetics need to be sonicated that 
facilitates their dissolution.  A 0.5 mM isoflurane corresponds to 1 minimal alveolar 
concentration and this concentration is usually used in APC studies. 
APC in stem cell regenerative medicine.  Stem cells and their derivatives have 
potential to be utilized for regeneration of organs, including heart, in addition to their use for 
disease modeling.  Dr. Murry’s group showed that the regeneration of myocardium damaged 
by acute ischemia-reperfusion by ESCs can be increased by two strategies: first, by using 
differentiated cardiomyocytes instead of undifferentiated stem cells, and second, by protecting 
engrafted cells from the noxious environment in the host tissue using a cocktail of pro-
survival factors.(5)  This was the first study that demonstrated the critical importance of 
actively protecting engrafted cells from the conditions in the infarcted myocardium.  The 
ability of implanted hESC-derived cardiomyocytes to repair I/R-injured myocardium critically 
depends on their ability to survive the stressful environment within the host tissue, which can 
be improved by enhancing their resistance to activation of cell death pathways using a pro-
survival cocktail.(5)  Interestingly, some components of the pro-survival cocktail have 
comparable effects to APC: inhibition of mPTP opening, (102) anti-apoptotic pathway 
activation (103) and opening of ATP-sensitive potassium channels.(83)  Unfortunately, it can 
be anticipated that the use of cocktail of agents in the clinical practice could be troublesome 
since each component needs to be approved by regulatory agencies and multiple drug 
treatments are likely to cause adverse drug interactions.  However, since majority of these 
pro-survival agents act similarly to a single treatment with APC, (80, 83), and since volatile 
anesthetics are already in the clinical use, APC could serve for protection of stem cell-derived 
cardiomyocytes in clinical practice. 
 
Reactive Oxygen Species in Anesthetic-induced Preconditioning 
Although excessive production of ROS causes damage to cardiomyocytes during 
reperfusion, a moderate increase in ROS production prior to prolonged ischemia-reperfusion 
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triggers endogenous cytoprotective mechanisms that protect the cell from the subsequent burst 
of ROS production.(52, 104)  ROS are crucial mediators of preconditioning signal, since 
antioxidants abrogate both ischemic- and anesthetic preconditioning.(52, 105, 106)  
Moreover, ROS can directly elicit preconditioning.(107)  Volatile anesthetics induce 
production of ROS by altering electron flux along the respiratory chain and thereby slightly 
increasing electron leak and incomplete reduction of oxygen molecules.(104)  Generated 
superoxide radical is precursor of other ROS. 
Volatile anesthetic isoflurane partially inhibits complex I of the respiratory chain in 
isolated cardiac mitochondria and isolated cardiomyocytes.(104, 108, 109)  This action 
increases ROS production, which is corroborated by observations that complex I inhibitor 
rotenone also elevates ROS production.(110)  In addition, isoflurane directly induces 
mitochondrial depolarization by opening mitochondrial KATP channels, which tends to 
accelerate the rate of electron flux along the respiratory chain.(111, 112)  Accelerated electron 
flux along the respiratory chain in combination with complex I inhibition may further enhance 
ROS production to reach levels sufficient to trigger preconditioning signals.(95, 104)  A 
preconditioning potency of two volatile anesthetics, desflurane and sevoflurane is in direct 
correlation with the amount of ROS generated during triggering phase of preconditioning with 
each anesthetic.(52)  This finding is another piece of evidence that ROS species are crucial 
mediators of preconditioning signaling cascade. 
Protein kinase C (PKC) is well characterized downstream target of ROS in 
preconditioning signaling cascade.(113)  It is a redox sensitive kinase that becomes activated 
after oxidation or calcium binding to its regulatory subunit.(113)  Inhibition of PKC by non-
selective inhibitor chelerythrine or by selective inhibitor of epsilon isoenzyme (myristoylated 
PKC-epsilon V1-2 peptide) abolishes APC-induced cytoprotection.(102)  This indicates that 
protein kinase C, as a downstream target of ROS signaling, is another critical component of 
signal transduction cascade.  A study has demonstrated that upon activation protein kinase C 
translocates to mitochondria where it activates mitochondrial KATP (mitoKATP) channels.(114)  
ROS signaling and redox activation of protein kinase C is not only important for 
preconditioning, but it also underlies increased resistance of cancer cells.(113)  Therefore, this 
cytoprotective signaling seems to be part of general mechanism allowing cells to survive 
harsh conditions associated with hypoperfusion, hypoxia and oxidative stress. 
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Mitochondrial ATP-sensitive Potassium Channels in Anesthetic-induced Preconditioning 
 Inhibition of mitoKATP channels by 5-hydroxydecanoate (5-HD) either during 
signaling or memory phase of preconditioning abrogates APC.(97, 112)  This demonstrates 
that opening of these channels is a part of preconditioning signal transduction cascade, and 
also an important effector of cytoprotection.  During the signaling phase of APC opening of 
mitoKATP channels can slightly increase ROS production.(95, 115)  However, in stressed cells 
that are preconditioned (memory phase of APC) mitoKATP channel opening may prevent 
excessive generation of ROS due to partial depolarization of mitochondria.(80)  Namely, it 
has been demonstrated that small changes in mitochondrial membrane potential have 
substantial effect on ROS production at near-normal mitochondrial potentials.(80, 116, 117)  
Therefore, during reperfusion mitochondrial depolarization by mitoKATP channel opening 
may reduce the burst of ROS and therefore contribute to increased cell survival elicited by 
APC. 
 Opening of mitoKATP increases potassium flux into mitochondria lowering 
mitochondrial membrane potential (normal is estimated between 160 and 200 mV).(118-120)  
High mitochondrial membrane potential impedes electron flux along the respiratory chain 
thereby increasing electron leak and ROS formation.  Restoration of mitochondrial membrane 
potential during early reperfusion facilitates ROS burst in combination with rapid electron 
flux stimulated by oxygen repletion.(121)  Therefore, opening of mitoKATP channels can 
attenuate this ROS burst in early reperfusion by slightly depolarizing mitochondria.  
 This partial mitochondrial depolarization can also attenuate mitochondrial calcium 
overload during ischemia-reperfusion, since calcium is driven into mitochondria by 
mitochondrial membrane potential.(76, 111, 122, 123)  Mitochondrial calcium overload 
together with ROS burst facilitate opening of mPTP that further exacerbates cell injury.(57, 
64, 102)  Attenuation of ROS production by slight mitochondrial depolarization can also 
attenuate calcium release from the sarcoplasmic reticulum by ryanodine receptor and also 
improve cellular calcium expulsion by sarcoplasmic reticulum calcium ATP-ase.(67, 124)  
Both of them are redox sensitive.(125)  This decreases cytosolic and mitochondrial calcium 
overload.  Beneficial effects of partial mitochondrial depolarization for cell survival during 
simulated reperfusion injury have been demonstrated with the use of 2,4-dintrophenol.(80)  
Namely, when 2,4-dintrophenol was used in s dose that mimics mitochondrial depolarization 
elicited by APC, it produced substantial cytoprotective effects that included attenuation of 
excessive ROS production, attenuation of cytosolic and mitochondrial calcium accumulation, 
delay in mPTP opening and improved cell survival.  These cytoprotective effects were 
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quantitatively similar to those elicited by APC.  This was direct evidence that partial decrease 
of mitochondrial membrane potential, likely by mitoKATP channel opening, is a key effector 
of cytoprotection by APC.  
 
Mitochondrial Permeability Transition Pore Opening in Anesthetic-induced 
Preconditioning 
 Opening of the mPTP is the crucial step during ischemia reperfusion that exacerbates 
cell injury and initiates cell death pathways, necrosis and apoptosis.(56, 57)  Excessive 
production of ROS and intramitochondrial calcium accumulation are two main triggers of 
mPTP opening, which results in rapid and complete collapse of mitochondrial membrane 
potential.(126)  The affected mitochondrion stops producing ATP thereby accelerating 
progression towards necrotic cell death.(126, 127)  Pore opening also allows mitochondrial 
influx of various solutes, leading to mitochondria swelling and rupture of outer mitochondrial 
membrane that has a smaller surface area than the inner mitochondrial membrane.  The 
rupture of the outer mitochondrial membrane allows the release of cytochrome c from the 
intermembrane space, which will initiate apoptotic pathways by initiating cascade caspase 
activation.(126, 127)  Moreover, second mitochondria-derived activator of caspases 
(SMAC/DIABLO) and apoptosis-inducing factor (AIF) are also released from mitochondria 
further stimulating caspase-dependent and caspase-independent apoptotic pathways, 
respectively.(126, 128)  Although mPTP opening initiates apoptotic cell death, the number of 
unaffected mitochondria by the mPTP opening, i.e. the amount of ATP in the cell, will 
determine whether the cell will undergo energy-dependent apoptosis or energy independent 
necrosis.(126) 
 The structure of the mPTP has been debated over the long time and its constituents are 
still unclear.  Initially, it was thought that the pore was formed jointly by the adenine 
nucleotide translocator (ANT) on the inner mitochondrial membrane and the voltage 
dependent anion channel (VDAC) on the outer membrane.(129)  However, knockout studies 
showed that the pore can be formed in the absence of either component although a greater 
amount of stress was required to induce pore opening.(130-132)  The important regulator of 
the mPTP is cyclophilin D, whose inhibitor cyclosporine A is the most widely accepted 
experimental pore inhibitor.(129)  Although the pore structure is still under investigation, it is 
known that the pore allows free passage of solutes up to 1.5 kDa in size.(126)  Direct 
inhibition of the pore by cyclosporine A attenuates infarct size in vivo demonstrating its 
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critical role in ischemia-reperfusion injury.(133, 134)  Several studies demonstrated that APC 
induces cardiac cytoprotection by delaying opening of the mPTP.(80, 102)  
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2. HYPOTHESIS 
 
The general hypothesis of the doctoral dissertation is: human pluripotent stem cell-
derived cardiomyocytes exhibit competent responses to preconditioning with volatile 
anesthetic isoflurane and therefore can be used as a valid model to study APC in vitro. 
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3. AIMS 
 
 The overall objective of this doctoral dissertation is to investigate cardiomyogenesis in 
human pluripotent stem cells lines and to investigate competence of these cardiomyocytes as 
an experimental model for studying APC.  
 
Specific Aim 1:  To optimize methodology for differentiation of cardiomyocytes from 
human pluripotent stem cells. 
 
Specific Aim 2:  To investigate feasibility of using human cardiomyocytes differentiated 
from pluripotent stem cells for studying mechanisms of APC in vitro. 
 
Specific Aim 3:  To investigate the process of cardiomyogenesis and efficiency of 
cardiomyocyte differentiation in hiPSC lines.  
 
The doctoral dissertation focused on the differentiation of cardiomyocytes from two 
types of human pluripotent stem cells, hESCs and hiPSCs.  Approach called “directed 
differentiation” was utilized in this dissertation to generate hESC-derived cardiomyocytes and 
hiPSC-derived cardiomyocytes with high efficiency.  It relies on the induction of 
cardiomyogenesis by application of endoderm-secreted growth factors that have been shown 
to favour cardiac differentiation and thereby can improve efficiency of cardiomyogenesis.  
Commercially available lines of hESC were utilized, and experiments with these cells were 
conducted at the Medical College of Wisconsin.  hiPSC lines were obtained from the 
laboratory of Dr. S. A. Duncan, MCW.  The efficiency of APC in human pluripotent stem 
cell-derived cardiomyocytes was studied by testing characteristic mediators of APC 
previously identified in human adult cardiomyocytes. 
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4. MATERIALS AND METHODS 
 
Human embryonic stem cell and human induced pluripotent stem cell culture 
Human ESC lines H1 and H9 (135) were purchased from the National Stem Cell Bank 
(NSCB; WiCell, Madison WI).  hiPSC lines C2a and C6a were induced from human foreskin 
fibroblasts (ATC #CRL2097) as previously described (10) by transduction with lentivirus-
encoded Oct4, Sox2, Nanog and Lin28.  Pluripotent cells were maintained under hypoxic 
conditions (4% O2, 5% CO2) on mouse embryonic fibroblasts (MEFs) inactivated with 
mitomycin C (#M0503; Sigma-Aldrich, St Louis, MO), in medium consisting of DMEM/F12 
(#11330-032, Invitrogen, Carlsbad, CA) supplemented with 20% knock-out serum 
replacement (#10828-028; Invitrogen), 1% non-essential amino acids, 1% penicillin-
streptomycin (#15140-148, Invitrogen), L-glutamine (#25030-081, Invitrogen), 100 µM ß-
mercaptoethanol (#M-6250, Sigma-Aldrich) and 4 ng/mL human recombinant basic fibroblast 
growth factor (#PHG0026, AA 10-155, Invitrogen).  Colonies of ESCs and iPSCs were 
passaged every five days by manual microdissection with a 27-gauge needle to create ~500 
µm2 clumps, followed by a 1  4 split.   
 
Cardiac differentiation of hESCs and hiPSCs 
To differentiate pluripotent cells into cardiomyocytes, we used “directed 
differentiation” previously described.  A schematic representation of differentiation protocol 
is depicted in Figure 2.  Briefly, colonies were mechanically dissected into small clumps that 
were plated onto wells of a 6-well dish (without MEFs) that had been pre-coated with 
Reduced Growth Factor Matrigel (354230; BD-Biosciences, San Jose, CA) at a final 
concentration of 0.05 mg/ml in DMEM/F12; counting of cells dissociated from clumps 
estimated that each well contained 250,000 cells.  For the next seven days pluripotency was 
maintained under hypoxic conditions using human ESC medium that had been conditioned by 
MEFs during the previous 24-hours period (i.e. MEF-conditioned medium).  To induce 
differentiation, medium was exchanged for RPMI Medium 1640 (#22400, Invitrogen) 
fortified with B-27 Serum-Free Supplement (#17504-044, Invitrogen, which contains a 
proprietary amount of insulin), supplemented with activin-A (50 ng/ml; #338-AC, R&D 
Systems, Minneapolis, MN) and BMP4 (10 ng/ml; 314-BP-010 R&D Systems) and the 
cultures were placed in normoxic conditions; this time point is referred to as “day 0”.  After 
five days’ induction with activin-A and BMP4, these growth factors were removed and 
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differentiation was continued in RPMI/B27/insulin alone.  Cultures were monitored daily for 
the onset of spontaneous contractions.   
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Figure 2. Experimental scheme for inducing the cardiomyogenic lineage in clumps of 
pluripotent hESCs and hiPSCs. hESCs, human embryonic stem cells; hiPSCs, human 
induced pluripotent stem cells; MEF, mouse embryonic fibroblasts; BMP4, bone 
morphogenetic protein 4; cTnT, cardiac troponin T 1.  Published in (136). 
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Microdissection and single cell dissociation 
After 90 days from treatment with growth factors, the beating cell clusters were 
mechanically dissociated from the remaining cell aggregates under a dissecting microscope 
(SMZ1000, Nikon, Japan) and treated with 0.05 % trypsin-EDTA (Invitrogen) for 4 min to 
dissociate individual cells, which were plated onto Matrigel-coated coverslips. 
 
Immunostaining 
Cardiomyocytes derived from ESCs and iPSCs were characterized by immunostaining 
40 days after induction of differentiation.  Cells were fixed in 1% paraformaldehyde for 1 hr 
and permeabilized with 0.5% Triton X-100 for 30 min.  Cultures were rinsed 3x with PBS, 
blocked with 3% bovine serum albumin/PBS, followed by 3x rinses with PBS.  Primary 
antibodies prepared in 1% BSA/PBS were applied overnight at 4˚C.  The following primary 
antibodies were used: anti-α-actinin (1:100; A37732, Sigma) and anti-troponin T (1:100; 
AMPA6687, Thermo Scientific, Rockford, IL) and anti-titin (1:200; 9D10, Developmental 
Studies Hybridoma Bank, Iowa City, IA).  Primary antibodies were rinsed 3x with PBS, 
followed by application of appropriate secondary antibody labeled with Alexa Fluor 488 
(1:1000; A21202 Invitrogen).  Secondary antibodies diluted in 1% BSA/PBS were applied for 
2 hr on a rotator.  Cells were rinsed 3x with PBS and nuclei were stained with TOPRO-3 
(1:1,000; T3605, Invitrogen) for 10 min.  Images were acquired using a laser-scanning 
confocal microscope (Eclipse TE2000-U; Nikon, Tokyo, Japan) and analyzed using 
MetaMorph 6.2 software (Universal Imaging, West Chester, PA). 
 
Identification of Cardiomyocytes in Beating vs. Non-beating Areas 
Percentages of cardiomyocytes in beating and non-beating areas of the culture dishes 
were determined as follows.  Cells in each area were isolated using a 27-gauge needle under 
the dissecting microscope (SMZ 1000; Nikon, Tokyo, Japan) and enzymatically dispersed in 
0.05 % trypsin-EDTA (Invitrogen) for 4 min, after which trypsin was inactivated by adding 
DMEM (SLM-021-B; Millipore) containing 20% FBS (16000-044; Invitrogen).  Dissociated 
cells were pelleted (3 min @2,800 g), resuspended in RPMI/B27, counted and plated onto 
Matrigel-coated glass coverslips at low density (~1,000 cells/cm2).  Two days later, the cells 
were transduced with lentiviral particles encoding human MLC 2v-driven EGFP.  Four days 
later the transfected cells were counter-stained with TMRE (T669, Invitrogen), a 
mitochondrial marker used to identify all cells in the population, followed by enumeration of 
EGFP-positive cells as a percentage of TMRE-positive cells as previously described;(137) a 
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minimum of 500 randomly selected TMRE-positive cells were enumerated on each coverslip.  
The MLC 2v-EGFP lentiviral construct was a generous gift from the laboratory of Dr. Lior 
Gepstein (Technion-Israel Institute of Technology, Haifa, Israel.(138)  Prior to use, the MLC 
2v-EGFP cassette was subcloned into transfer plasmid pHR(+)c.Ub.MCSoligo.R(-)W(+) 
(which does not contain a CMV promoter), followed by production and titering of lentiviral 
vector as described previously.(139, 140) 
 
Laser-scanning confocal microscopy 
Four days after lentiviral vector transduction, imaging was performed using a confocal 
microscope (Eclipse TE2000-U, Nikon) and data were analyzed with MetaMorph 6.1 
software (Universal Imaging, West Chester, PA).  Living hESC- and hiPSC-derived 
cardiomyocytes were identified by detecting fluorescence of MLC 2v-driven EGFP-positive 
cells and experiments were conducted in Tyrode’s solution (in mM: 132 NaCl, 10 HEPES, 10 
glucose, 5 KCl, 1 CaCl2, 1.2 MgCl2, pH 7.4) at room temperature.  The percentage of hESC-
derived cardiomyocyte death was determined after exposing cells to oxidative stress induced 
by 10 mM H2O2 (Calbiochem) applied for 50 min, followed by perfusion with Tyrode’s 
solution for 10 min.  The cells stained with red-fluorescent propidium iodide (2 µM, Sigma-
Aldrich) were considered dead.(47)  hESCs- and hiPSC-derived cardiomyocytes were 
preconditioned with 0.5 mM isoflurane (APC) applied for 15 min, followed by 5 min 
isoflurane washout.  After each experiment, a gas chromatography was used to test isoflurane 
concentrations, which varied ±10% of reported values.  The tetramethylrhodamine ethyl ester 
(TMRE, 30 nM, Invitrogen) was used to detect ∆Ψm in hESC-derived cardiomyocytes.  ROS 
production was monitored in cells loaded with dihydroethidium (10 µM, Invitrogen).  
Opening of the mPTP was assessed as previously described in our laboratory,(102) a method 
based on mPTP induction by photoexcitation-generated oxidative stress.(79, 141-143)  The 
mPTP opening was detected by rapid dissipation of ∆Ψm, observed as loss of TMRE 
fluorescence, which is sensitive to mPTP opening inhibition.(102) The mPTP opening was 
assessed in hESC-derived cardiomyocytes and hiPSC-derived cardiomyocytes. 
 
Electrophysiology 
Membrane potential (Em) was measured in microdisscted beating clustures using 3M 
KCl-filled borosilicate glass (FHC) microelectrodes (impedance 40-60 MΩ) in RPMI/B27 
medium.  Data were processed using a Grass RPS7C polygraph (Astro-Med/Grass Inc) and 
Superscope II digital data acquisition system (GW Instruments) 
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Oxygen consumption 
Spontaneously and rhythmically contracting cell clusters of hESC-derived 
cardiomyocytes were separated by microdissection and respiration of cell clusters that 
predominantely contain cardiomyocytes was measured using an oxygen electrode (Hansatech 
Instruments, Norfolk, UK) at 37ºC.  Isoflurane was delivered at incremental steps and the rate 
of oxygen consumption after each isoflurane addition was normalized to baseline values. 
 
Real-Time PCR 
Expression of genes expressed during cardiomyogenic differentiation was assessed by 
real-time quantitative PCR (qPCR).  Beginning at the time of induction (day 0), cells were 
harvested on alternate days during the first 20 days, followed by harvest of a terminal time 
point on day 40.  RNA purification and qPCR were performed as previously described.(137)  
Briefly, cells were lysed, vigorously pipetted and stored at -80˚C until purification.  
Immediately after thawing, total RNA was purified using the RNeasy Mini Kit (#74104, 
Qiagen, Valencia, CA), with Qiashredder (#79654, Qiagen), per the manufacturer’s 
instructions.  Following quantification at A260, 1.0 µg total RNA from each sample was 
reverse-transcribed (#C-03 RT2 First Strand Kit, SABiosciences, Frederick, MD).  qPCR was 
performed by adding 10 µl of each RT product to 90 µl master mix (#PA-011 RT2 SYBR 
Green/Fluorescein qPCR Master Mix, SABiosciences) in wells of 96-well plates containing 
custom pre-arrayed primer pairs (Custom RT2 Profiler PCR Array, SABiosciences) to amplify 
the mRNAs described in Figure 14.  PCR reactions were performed using an iCycler (BioRad, 
Hercules, CA).  Each time point in Figure 14 is the average of duplicate dishes. 
 
Statistical analyses 
Data are presented as mean ± SD.  Each experimental group comprises hESC-derived 
cardiomyocytes from at least 3 different differentiations, where n indicates the number of 
independent experiments.  Statistical comparisons were performed using one-way analysis of 
variance with Bonferroni's post hoc test.  Differences at P<0.05 were considered significant.  
The t test was used to analyze differences in experiments with only two groups. 
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5. RESULTS 
 
In the first part of the dissertation we investigated whether cardiomyocytes derived 
from hESCs can be used as a complimentary experimental model of human cardiomyocytes to 
study APC.  We also analyzed whether hiPSC-derived cardiomyocytes exhibit similar 
responses to APC as hESC-derived cardiomyocytes in terms of the opening of the mPTP. 
To identify the possibility that hESC-derived cardiomyocytes have the competent 
endogenous protective mechanisms against oxidative stress to be used as an experimental 
model for APC, we investigated whether preconditioning with the anesthetic isoflurane elicits 
distinct mediators of protection in these cells: reactive oxygen species (ROS) and opening of 
mitochondrial ATP-sensitive potassium (mitoKATP) channels as signal mediators, and a delay 
in mPTP opening as an endpoint of protection.  The model was validated by comparing 
obtained results to our previous work using adult human and adult animal cardiomyocytes.   
 
Differentiation and characterization of hESC-derived cardiomyocytes 
The presence of cardiomyocytes after cardiac differentiation of hESCs was observed 
as occurrence of spontaneously and rhythmically beating areas of contiguous cells in culture 
dishes, beginning approximately 10 days after treatment with activin-A and BMP4 and lasting 
up to a one year (please see link: http://links.lww.com/ALN/A624).  As shown in Figure 3, 
immunostaining revealed an abundance of cells positive for cardiac specific sarcomeric 
proteins, organized in characteristic striated pattern (Figure 3A, B, C, D).  Following the 
dissociation from culture dishes, cardiomyocytes retained their striated appearance (Figure 
3F), with some continuing to exhibit spontaneous rhythmic contractions (please see link: 
http://links.lww.com/ALN/A625).  Short (<130 ms) atrial-like action potentials, and long 
(>250 ms) ventricular-like action potentials, were recorded in dissociated, contracting cell 
clusters, indicating electrical activity and existence of functional sarcolemmal ion channels in 
these cardiomyocytes.  
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Figure 3. Immunolabeling and electrophysiological characterization of hESC-derived 
cardiomyocytes.  Confocal images of non-dissociated cells after 90 days from treatment with 
growth factors, and stained for cardiac sarcomeric proteins: (A) sarcomeric α-actinin, (B) 
cardiac-specific cTnT, (C) titin, and (D) cardiac-specific MLC 2a. A large percentage of 
positive cells are observed, including striated patterns indicating highly organized sarcomeres. 
(E) Occasional occurrence of cells with rod-shaped morphology that resemble adult 
cardiomyocytes. (F) Dissociated cell stained for cTnT showing that cells maintain sarcomeric 
organization after dissociation. (H) A dissociated cell that is spontaneously and rhythmically 
contracting. (G) Representative recordings of action potentials: shorter, atrial-like (upper 
trace) and longer, ventricular-like (lower trace).  Published in (137).  
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Genetic marking and labeling of live hESC-derived cardiomyocytes using a lentiviral vector 
To identify living hESC-derived cardiomyocytes and determine differentiation 
efficiency, differentiated cells were genetically marked using a self-inactivating lentiviral 
vector containing a cardiac-specific promoter MLC 2v driving the expression of EGFP 
(Figure 4A).  Lentiviral transduction efficiency, determined with ubiquitin-driven EGFP, was 
98±1% (Figure 4B).  The 85±3% of cells were MLC 2v-EGFP-positive, i.e. ventricular 
myocytes, indicating high efficiency of our differentiation protocol (Figure 4B,C). 
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Figure 4. Labeling and counting of hESC-derived cardiomyocytes using lentiviral 
vector. (A) Schematic representation of lentiviral vectors, pHR(+)c.MLC 2v.EGFP.R(-)W(+) 
and pHR(+)c.Ub.EGFP.R(-)W(+) used for identifying cardiomyocytes and determining 
transduction efficiency, respectively. (B) To determine the total cell number in beating 
clusters, after dissociation cells were loaded with TMRE (red) to visualize cell bodies.  MLC 
2v-EGFP-positive cells were counted by detecting green fluorescence, giving the number of 
ventricular myocytes. (C) Summarized data from five separate differentiation experiments 
show high percentage of hESC-derived cardiomyocytes.  Published in (137).  
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APC protects hESC-derived cardiomyocytes from oxidative stress 
To test whether APC protects the hESC-derived cardiomyocytes from oxidative stress-
induced cell death, the preconditioned and control cells, were exposed to H2O2.  The 
cardiomyocytes were identified as MLC 2v-EGFP-positive cells (green-fluorescent cells in 
Figure 5A).  APC attenuated the hESC-derived cardiomyocyte death compared to control, 
32±7%, vs. 58±7%, n=5, respectively (Figure 5B,C).  This correlates with our previous study 
which showed that APC protects adult human atrial cells from oxidative stress.(100) 
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Figure 5. hESC-derived cardiomyocytes are protected from oxidative stress by APC. (A) 
MLC 2v-EGFP-positive cells, i.e. hESC-derived cardiomyocytes, were identified by green 
fluorescence using confocal microscopy.  Following exposure to oxidative stress and 
3compared to control (Ctrl), APC decreased the number of hESC-derived cardiomyocytes that 
stained positive for red-fluorescent propidium iodide (PI), an indication of cell death. (B) The 
rate of increase in number of PI-positive cells, expressed as percent of total number of hESC-
derived cardiomyocytes, is attenuated in APC group compared to Ctrl. (C) Summarized 
values after the application of H2O2, following 10 min of perfusion with Tyrode solution.  
*
P<0.05 vs. Ctrl.  Published in (137).  
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Isoflurane depolarizes mitochondria in hESC-derived cardiomyocytes by opening mitoKATP 
channels 
Using adult rat cardiomyocytes, we have previously shown that isoflurane induces 
opening of mitoKATP channels causing decrease in ∆Ψm and thereby eliciting 
cardioprotection.(111)  In hESC-derived cardiomyocytes, diazoxide, an opener of mitoKATP 
channels,(144) decreased TMRE fluorescence intensity to 87.9±1.8% of baseline (n=11), 
indicating opening of mitoKATP channels (Figure 6) Application of 0.5 mM isoflurane 
decreased TMRE fluorescence intensity to 80.8±3.5% of baseline (n=11).  This was 
attenuated in the presence of 5-hydroxydecanoate (5-HD), an inhibitor of mitoKATP channel 
opening (144) (91.5±1.0% of baseline, n=11), indicating that mitochondrial depolarization by 
isoflurane is, in part, mediated by opening of mitoKATP channels.  
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Figure 6. Isoflurane opens mitoKATP channels and depolarizes mitochondria in hESC-
derived cardiomyocytes.  ∆Ψm was monitored in dissociated hESC-derived cardiomyocytes 
using TMRE fluorescence.  The time point when drugs were added is indicated by the arrow.  
Diazoxide (50 µM) decreased TMRE fluorescence intensity, indicating mitochondrial 
depolarization.  Application of isoflurane (Iso) also decreased TMRE fluorescence intensity, 
an effect that was partly blocked with 200 µM 5-HD.  2,4-dinitrophenol (DNP; 100 µM) 
completely depolarized mitochondria.  *P<0.05 vs. baseline; #P<0.05 vs. Iso + 5-HD.  
Published in (137). 
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Oxygen consumption by cell clusters containing hESC-derived cardiomyocytes is inhibited 
by isoflurane 
The rate of oxygen consumption of microdissected beating cell clusters that 
predominantly contained hESC-derived cardiomyocytes was monitored in the presence of 
incremental isoflurane concentration (Figure 7).  At a concentration of 0.12 mM, isoflurane 
slightly, but not significantly increased oxygen consumption.  However, by increasing 
isoflurane concentration to 0.25, 0.5 and 1.0 mM, the oxygen consumption progressively 
decreased to 98.1±6.8%, 88.7±6.6%, and 83.6±4.8% of baseline, respectively, (n=7).  This 
correlates with our data from adult rat cardiomyocytes, indicating partial obstruction of the 
electron transport chain (ETC) by isoflurane.(104) 
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Figure 7. Isoflurane attenuates hESC-derived beating cell cluster oxygen consumption.  
The rates of oxygen consumption in hESC-derived contracting cell clusters after the addition 
of incremental isoflurane (Iso) concentration isoflurane were normalized to baseline values.  
At the higher concentrations, isoflurane attenuated oxygen consumption.  DNP (100 µM) and 
cyanide (CN-, 2 mM) were added to establish maximal and minimal rates of oxygen 
consumption.  *P<0.05 vs. baseline.  Published in (137). 
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Isoflurane enhances production of ROS by hESC-derived cardiomyocytes 
Production of ROS, important signaling molecules in preconditioning of adult 
cardiomyocytes,(52, 145) was monitored in hESCs-derived cardiomyocytes (Figure 8).  Ten 
minutes after the addition of isoflurane (0.5 mM), Eth fluorescence increased to 120.0±3.3% 
of baseline (n=12) which is a significantly greater than in un-treated cells (101.5±0.7% of 
baseline, n=5).  This indicated that isoflurane increases ROS production in hESC-derived 
cardiomyocytes. 
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Figure 8. Isoflurane enhances ROS production in hESC-derived cardiomyocytes.  ROS 
production in hESC-derived cardiomyocytes was measured by detecting fluorescence 
intensity of ethidium (Eth).  Compared to the Time control, isoflurane (Iso) significantly 
increased Eth fluorescence intensity.  *P<0.05 vs. Time control.  Published in (137). 
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Preconditioning with isoflurane or hydrogen peroxide delays opening of mitochondrial 
permeability transition pore in hESC-derived cardiomyocytes 
Cardioprotective strategies, including APC delay opening of mPTP, a critical event in 
the transition towards cell death.  mPTP opening-induced dissipation of ∆Ψm was monitored 
in hESC-derived cardiomyocytes exposed to oxidative stress (Figure 9).  Similarly to mPTP 
inhibitor cyclosporine A (CsA, 1 µM), APC delayed the mPTP opening occurred (Figure 9B).  
APC and preconditioning with H2O2 increased arbitrary mPTP opening time to 139.4±10.1 
(n=16) and 130.5±9.0% of control (n=12), respectively, indicating that each treatment elicited 
preconditioning and delayed mPTP opening (Figure 9C).  Application of 5-HD together with 
isoflurane abrogated APC-induced increase in arbitrary mPTP opening time (95.3±2.9% of 
control, n=16) confirming the role of mitoKATP channel opening in signal mediation of APC. 
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Figure 9. Preconditioning delays mPTP opening in hESC-derived cardiomyocytes. (A) 
mPTP opening was induced by photoexcitation-generated oxidative stress and detected by 
rapid dissipation of TMRE fluorescence. (B) Representative signal traces from control (Ctrl), 
CsA-treated cells, and APC.  Arbitrary mPTP opening time was determined as the time when 
TMRE fluorescence intensity decreased by half between initial and residual fluorescence 
intensity. (C) mPTP blocker CsA and APC increased arbitrary mPTP opening time, which 
was blocked in presence of 5-HD (APC + 5-HD).  Preconditioning with 40 µM H2O2 (H2O2-
PC) also delayed mPTP opening.  *P<0.05 vs. Ctrl; #P<0.05 vs. APC + 5-HD.  Published in 
(137).  
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Preconditioning with isoflurane delays opening of mitochondrial permeability transition 
pore in hiPSC-derived cardiomyocytes 
 mPTP opening time was determined in hiPSC-derived cardiomyocytes using a similar 
experimental protocol as for hESC-derived cardiomyocytes.  The arbitrary mPTP opening 
time induced by oxidative stress was greater in hiPSC-derived cardiomyocytes exposed to 
APC (136.6±8.3% of control, n=5) than in control cells (102.4±23.8% of control, n=5), as 
shown in Figure 10.  This indicated that preconditioning with isoflurane elicited effective 
endogenous cytoprotective mechanisms that induced the delay in mPTP opening in hiPSC-
derived cardiomyocytes.   
  
43 
 
 
 
 
 
 
 
 
Figure 10. APC delays mPTP opening in hiPSC-derived cardiomyocytes.  mPTP opening 
was induced by photoexcitation-generated oxidative stress.  A drop in the initial TMRE 
fluorescence intensity by 50% was compared between experimental groups (as in Figure 9).  
Preconditioning with isoflurane increased arbitrary mPTP opening time compared to control.  
*
P<0.05 vs. Ctrl. 
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With the results presented so far we have demonstrated an efficient method to 
differentiate cardiomyocytes from hESCs, indicated by genetic labeling using lentiviral 
vectors, showing that ~85% of cells in beating clusters expressed cardiac-specific promoter 
MLC 2v.  Efficient differentiation and a phenotype of functional cardiomyocytes was also 
indicated by observing globally contracting cell clusters that widely expressed highly 
organized, cardiac-specific sarcomeric proteins and generated action potentials resembling 
those of mature heart cells.  Moreover, we showed that preconditioning with isoflurane 
attenuates cell death and elicits competent mechanisms of protection in ventricular hESC-
derived cardiomyocytes against oxidative stress.  These included characteristic and important 
mediators of cardioprotection: opening of mitoKATP channels, partial inhibition of the ETC, 
ROS as signaling molecules, and a delay of oxidative stress-induced mPTP opening, an end-
point of protection.  APC also induced the delay in mPTP opening in hiPSC-derived 
cardiomyocytes.  Similar responses to APC between adult cardiomyocytes documented in our 
previous studies and hESC-derived cardiomyocytes demonstrated in this study indicate the 
feasibility of using hESC-derived cardiomyocytes as a model of human ventricular cardiac 
cells to study APC and potentially other treatments/diseases. 
In the second set of experiments we tested and compared cardiomyogenic potential 
among hESC and hiPSC lines.  This was achieved using the same directed differentiation 
approach.  
 
Differentiation of Beating Cardiomyocytes is more Extensive in ESCs than in iPSCs 
We simultaneously compared the ability of two widely used ESC lines (H1 and H9) 
and two iPSC (C2a and C6a) lines to differentiate into beating cardiomyocytes, using 
identical conditions of induction and cell culture.  As described in Supplemental Figure 4 in 
the reference (10), pluripotent C2a and C6a iPSCs exhibit morphological, gene expression, 
and karyotype characteristics that are indistinguishable from pluripotent H9 ESCs.  Moreover, 
C2a and C6a iPSCs form teratomas containing cells from all three germ layers; these iPSCs 
can reproducibly and efficiently differentiate into hepatocytes in stepwise, directed fashion by 
sequential treatment with growth factors that induce liver development in the embryo.(10) 
In this experiment, all four lines were induced to differentiate in defined medium 
(RPMI/B27) supplemented with cardiomyogenic growth factors BMP4 and activin-A at time 
zero (day 0) for five days, after which the cells were treated with RPMI/B27 only, up to day 
40, by which time cells in all cultures had become confluent and multilayered (Figure 11).  
Although rhythmic beating was observed by day 10 in both ESC lines, contractions were not 
45 
 
observed in the iPSC lines until the fourth week.  In all lines, contractions were spontaneous 
and rhythmic, always occurring in cell clusters rather than in individual cells, which is 
characteristic of cardiomyocytes derived from pluripotent cells.(20, 146)  Figure 11 shows 
characteristic morphologies of cultures derived from each cell-line at day 40.  Corresponding 
videos showing the extent of rhythmic contractions throughout the culture dish on day 40 can 
be viewed by accessing the following link: 
http://www.mcw.edu/cellbiology/johnloughphd.htm.  In some instances (H1 ESCs), 
contractions were sustained for a year or longer (not shown).  Contractility was most 
extensive in H1 ESC cultures, wherein multilayered networks of contracting cells formed that 
were interconnected, nearly spanning the entire dish (Video Clip 1); in accord with our 
previous experience using H1 cells, this indicated that the contractile tissue was comprised of 
contiguous myocytes that were electrophysiologically synchronized.(137)  H9 ESCs also 
exhibited contractile three-dimensional areas (Video Clip 2); however, these were neither as 
networked nor as extensive as in cultured H1 ESCs.  By contrast, cultures containing iPSC 
lines C2a and C6a exhibited beating in only a few clumps of cells that were not 
interconnected (Video Clips 3 & 4); with time, contractile areas in iPSC cultures did not 
expand or become multilayered, in contrast to H1 and H9 ESCs. 
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Figure 11. Phase-contrast images of differentiated hESCs and hiPSCs after 40 days in 
culture. Representative light microscope images of hESC- and hiPSC-derived cells at high 
magnification (400x) on day 40 of differentiation.  Note that H1 and H9 hESCs formed 
multilayered confluent cluster of cells that exhibited spontaneous rhythmic contractions 
(viewed in Video Clips 1 and 2).  hiPSC lines (C2a and C6a) also form multilayered and 
interconnected cell clusters that also spontaneously and rhythmically contracted (Video Clips 
3 and 4); however, the hiPSC cells formed less confluent clusters than hESCs.  Published in 
(136).  
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Sarcomere Differentiation is more Extensive in ESCs than in iPSCs 
Immunostaining was performed 40 days after inducing differentiation to monitor 
presence of cardiac-specific proteins and their assembly into sarcomeres.  All panels of Figure 
12 show immunostaining patterns in rhythmically beating areas of the dish.  This revealed that 
cTnT and sarcomeric α-actinin were organized into clearly striated patterns in H1 and H9 
ESCs (Figure 12a-f).  However, striations in both iPSC lines (Figure 12h,k) were less 
conspicuous, and definitely not as widespread as in the ESC cultures (not shown), consistent 
with the abundance of beating clusters shown in the Video Clips.  It is also noteworthy that 
the titin immunostaining pattern was remarkably extensive only for H1 ESCs (Figure 12m,n), 
which displayed three-dimensional organization of sarcomeric structures.  These 
characteristics were less evident in H9 ESCs, and were almost completely absent in 
contractile areas of C2a and C6a iPSCs (not shown). 
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Figure 12. Immunostained cardiomyocytes derived from hESCs and hiPSCs. (a–l) 
Representative images of immunostained cardiac troponin T (cTnT) and sarcomeric a-actinin 
in all four cell lines at day 40.  Striated staining patterns indicative of sarcomeres are seen in 
all hESC and hiPSC lines; however, striations are most extensive in H1 cells, wherein titin 
immunostaining (m, n) reveals a level or sarcomeric networking that was not observed in the 
other cell lines.  Published in (136).  
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H1 ESCs Exhibit the most Extensive Cardiomyocyte Enrichment 
By day 40, accurate counting of immunostained cells could not be performed due to 
extensive multilayering.  As alternative, percentages of cells in ESC and iPSC cultures that 
were in the cardiomyogenic pathway were estimated from transduced MLC 2v-EGF.  For 
these determinations, areas containing beating and non-beating cells were microdissected 
from each culture at day 40 and sub-cultured onto coverslips at low cell density, followed by 
transduction of a lentivirus-encoded MLC 2v-EGFP construct, which is activated at an early 
stage of ventricular myocyte differentiation.  Four days later, cells containing MLC 2v-
activated EGFP were imaged (Figure 13A) and enumerated (Figure 13B).  Total cells were 
counted after counter-staining with TMRE, a supravital mitochondrial dye (see Figure 13A) 
we previously employed (137) to avoid having to fix cells on coverslips, which inexplicably 
caused extensive cellular losses.  The filled bars in Figure 13B depict percentages of EGFP-
positive cells from beating areas, revealing that the greatest percentage (86%) was from the 
H1 ESC cultures; by contrast, cells sub-cultured from beating clusters of the H9, C2a and C6a 
lines displayed only 65-67 percent EGFP-positive cells.  The empty bars in Figure 13B depict 
percentages of EGFP-positive cells from the non-beating areas, which surprisingly was nearly 
as extensive as the percentages of EGFP-positive cells from the beating areas. 
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Figure 13. MLC 2v activation in ESCs and iPSCs.  Cells differentiated from all ESC and 
iPSC lines were sub-cultured and transduced with a lentivirus-encoced MLC 2v-eGFP 
construct at day 40.  Four days later cells were imaged to detect EGFP and counter-stained 
TMRE.  (A) fluorescent images of TMRE-positive (red fluorescence, left column) denoting 
total cells, and EGFP-positive (green fluorescence middle column) cells denoting cells in the 
cardiomyogenic lineage.  (B) percentages of MLC 2v-EGFP-positive cells determined relative 
to numbers of total cells identified by TMRE mitochondrial staining.  Each bar indicate the 
mean ± SEM of three determinations; *P<0.05.   
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qPCR Monitoring of Marker Gene Expression  
Expression of selected mRNAs was monitored by qPCR at multiple points during the 
course of differentiation (Figure 14).  In all four lines, induction of differentiation at day 0 
was followed by diminishing levels of the pluripotency marker OCT4, concomitant with an 
immediate peak in expression of the mesendoderm marker brachury (T), followed by 
decreases; this pattern was as predicted for these markers.  The earliest phases of 
cardiomyogenic induction are characterized by expression of MESP1 (mesoderm posterior 
basic helix-loop-helix transcription factor 1), NKX2.5 and ISL1 (ISL LIM homeobox 1); 
expression of these markers was similar in all lines, except that expression of ISL1 was low in 
both iPSC lines but remarkably high in H9 ESCs.  As cardiomyocytes begin to terminally 
differentiate, they express mRNAs including GATA4, MEF2C, TNNT2, TBX20 (T-box 20), 
and MYL7.  Although these markers increased as expected during the second week of the 40 
day culture period, expression of TNNT2, TBX20 and MYL7 was remarkably low in both 
iPSC lines.  Expression of mRNAs encoding various ion channel genes (HCN4, SCN5A, 
CACNA1C, KCNH2, KCNJ2, KCND3) was also monitored, revealing that with the 
exception of HCN4 which peaked in all lines at day 6, all began to undergo steady, subtle 
increases late in the second week; however, no cell line-specific differences were noted.  
Finally, expression of mRNAs indicative of differentiation into ectodermal (paired box 6; 
PAX6) and endodermal (sex determining region Y-box 17; SOX17) lineages revealed that 
whereas all four lines exhibited strong SOX17 expression (300x-800x) during the first week, 
induction of ectoderm was minimal, with the exception of increased PAX6 levels in C2a 
iPSCs on days 4-12, and especially on day 40. 
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Figure 14. Gene expression during cardiomyogenesis in hESC and hiPSC lines. 
Expression of the indicated genes was monitored during the 40-day differentiation period by 
qPCR.  Each data point is normalized to values at day 0 (induction of differentiation).  
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and ribosomal protein L13a 
(RPL13A) served as loading controls.  Each point represents the mean of duplicate samples; 
vertical lines indicate the range.  Published in (136). 
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6. DISCUSSION 
 
Summary of the obtained results 
The results presented in this dissertation demonstrated that the undertaken directed 
differentiation of all tested human pluripotent stem cell lines results in high enrichment of 
cardiomyocytes especially in the beating areas.  Differentiated hESC-derived cardiomyocytes 
exhibit many characteristics of mature heart cells, including spontaneous beating, expression 
of contractile myofibrils and generation of mature action potentials.  These cells exhibit 
similar responses to APC as mature animal cardiomyocytes.  Namely, volatile anesthetic 
isoflurane moderately increased ROS production by partly inhibiting respiratory chain and 
induced opening of the mitoKATP channels in these cells.  Activation of these crucial signals 
of APC is qualitatively and quantitatively similar to previously published results using adult 
cardiomyocytes.  Moreover, APC delayed opening of the mPTP and reduced cell death after 
exposure to oxidative stress, which is comparable to previously published results using adult 
human and animal myocardium.  The results demonstrate the existence of competent 
endogenous mechanisms against oxidative stress, i.e. ischemia-reperfusion in hESC-derived 
cardiomyocytes and their responsiveness to APC, which indicates feasibility of using these 
cells as an in vitro model for testing APC.  Thus, it can be concluded that hESC-derived 
cardiomyocytes can be used as a valid experimental model of human cardiomyocytes for 
studying APC.  Our findings are in agreement with several other laboratories showing that 
stem cell derivatives are phenotypically comparable to mature cells and therefore could be 
used as a valid model for pharmacological testing. 
The experiments in chapter 5 showed that cardiac differentiation of hiPSC lines 
recapitulates cardiomyogenesis in hESCs, which are considered gold standard for pluripotent 
stem cells.  Similar to hESC, hiPSC lines exhibited high differentiation efficiency and the 
ability to generate contracting cell clusters.  Cardiac sarcomeric proteins expressed striated 
pattern and the hiPSC-derived cardiomyocytes were positive for genetic labeling with cardiac-
specific marker MLC 2v-EGFP.  Temporal expression profile of pluripotency, early and late 
cardiac differentiation genes in hESC and hiPSC lines was in general comparable to 
previously published results, in spite of sporadic alterations in the expression profile for some 
individual genes and lines.  Altogether, this indicated an appropriate cardiomyogenesis in 
both hESC and hiPSC lines.  Cardiac differentiation efficiency was similar in hESC and 
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hiPSC lines, with the exception of H1 line that showed approximately 20% better results, 
which correlated with the greatest size of beating areas in this line.  Similar to hESC-derived 
cardiomyocytes, hiPSC-derived cardiomyocytes also respond to APC by eliciting endogenous 
protective mechanisms against the oxidative stress that resulted in a delay in mPTP opening.  
All these results support the hypothesis that hiPSC-derived cardiomyocytes can be used for in 
vitro testing of APC, just like hESC-derived cardiomyocytes. 
 
Cardiac differentiation of pluripotent stem cells 
In this dissertation we achieved highly efficient differentiation of human 
cardiomyocytes from H1 hESCs, obtaining unprecedented levels of ~85% of cells positive for 
the cardiac-specific marker MLC 2v in beating cell clusters.  An abundance of 
cardiomyocytes was corroborated by cardiac-specific immunostaining.  Moreover, areas with 
spontaneously and rhythmically beating cells, a characteristic of cardiomyocytes, spanned the 
entire surface of the culture dish (please see link: http://links.lww.com/ALN/A624).  hESC 
and hiPSC lines used here were previously tested for their pluripotency.(10-12)  Cardiac 
differentiation of these cells was obtained by mimicking natural induction of 
cardiomyogenesis by endodermal signaling using growth factors activin-A and BMP4 in a 
RPMI/B27 medium.  This approach is called directed differentiation.(147)  Unlike commonly 
used EB approach that relies on spontaneous differentiation of different cell types, whereby 
cardiomyocyte enrichment is relatively poor, the directed differentiation yields a great number 
of cardiomyocytes.(11, 148) 
We have applied BMP, FGF and activin-A, all endoderm-secreted growth factors, to 
direct differentiation into cardiac lineage, based on findings that endoderm-induced 
cardiomyogenic signaling regulates heart development in the embryo.(26)  Previously 
published protocols utilizing same growth factors were modified in this study.(20, 29)  
Namely, pluripotent cells were exposed to activin-A at a relatively high level (50 ng/ml) for 
an extended period of time (five days).  We speculate that this optimized the efficient 
production of mes-endoderm (149) leading to progressive differentiation into the 
cardiomyogenic lineage.  Our results compare highly favorably with other studies and 
approaches to differentiate cardiomyocytes, especially with a widely used method involving 
spontaneous differentiation termed embryoid bodies that yields low percentage of 
cardiomyocytes (≤10 %).(150) 
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More than 55% and 65% of cardiomyocytes was obtained in non-beating and beating 
areas, respectively, for hiPSC and hESCs.  The greatest cardiac differentiation was achieved 
in H1 hESC line where 75% and 85% of cardiomyocytes was detected in non-beating and 
beating areas, respectively.  These results indicate that directed differentiation is superior 
methodology for obtaining enriched human cardiomyocytes than the EB approach.  Other 
approaches targeting specific signaling pathways have also produced promising results and 
high cardiac enrichment.  Wnt/β-catenine signaling pathway is important for cardiac 
differentiation.  Its inhibition or stimulation at the specific time points of cardiomyogenesis 
can increases cardiomyocyte yield.(151)  These seemingly contradicting data are further 
indicating complexity of the cardiac differentiation process whereby positive regulation by 
certain signaling pathways at the early stage of differentiation, such as Wnt/β-catenine 
pathway can become negative regulator at the later stages of differentiation.  Therefore, it was 
very important in our protocol to restrict the treatment of human pluripotent stem cell lines 
with cardiomyogenic factors only to early differentiation stages and not throughout the 
differentiation process.   
Tissues that build the heart are composed of three main mesoderm-derived cell 
lineages, the cardiomyocyte, the vascular smooth muscle and the endothelial cell lineages.  
There are four main steps which are necessary for derivation of cardiomyocytes from 
pluripotent stem cells: 1) formation of mesoderm; 2) commitment of mesoderm toward 
anterior mesoderm/cardiogenic mesoderm; 3) formation of cardiac mesoderm and 4) 
generation of early cardiomyocytes.(24, 27)  The differentiation of pluripotent cells in vitro 
following these steps can be determined by characterization of the expression pattern of 
transcription factors characteristic for each step of the process.  Pluripotent stem cells are 
characterized by the expression of OCT4 and NANOG which are diminishing upon the 
induction of the differentiation process.(22)  The qPCR experiments presented here show that 
the expression of pluripotency factor OCT4 immediately decreases in all hESC and hiPSC 
lines, indicating the loss of pluripotency.  Downregulation of OCT4 is accompanied with 
upregulation of SOX17, an endodermal marker, which is in line with the induction of 
endodermal signaling with activin-A and BMP4.  The results also show early and transient 
increase in T/Brachyury expression in all tested lines.  It is expressed during the specification 
of certain cells from primitive streak toward the mesoderm. 
The expression of MESP-1 and ISL-1 is associated with specification of cardiac 
mesoderm and the expression of NKX2.5, TBX5, TBX20, GATA4, MEF2c and HAND1/2 
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with generation of cardiac progenitors.(24, 27)  Here it was shown that early stages of 
cardiomyogenesis are characterized by transient increase in the expression of MESP1, 
NKX2.5 and ISL1, while GATA4 and TBX20 exhibited steady and progressively increasing 
pattern of expression, respectively.  PAX6, an ectodermal marker, did not show any 
significant expression during the differentiation of cardiac myocytes except for the hiPSC-
C2a cells.  This could indicate less efficient cardiac mesodermal and later cardiac 
differentiation in this specific cell line.  Cardiac development is a complex and dynamic 
process accomplished through the sequential expression of signal transduction proteins and 
transcription factors.  The major signaling pathways involved in the development of heart are 
Wnts/Nodal, BMPs and FGFs.(24, 26, 27) 
Electrical activity of cardiomyocytes.  The most prominent evidence of cardiac 
differentiation of hESC and hiPSC lines was observation of spontaneously and rhythmically 
beating areas.  This indicates the presence of electromechanically competent cardiomyocytes 
that form the functional syncytium, which allows them to respond to electrical stimuli and to 
contract synchronously.  The spreading of action potentials among cardiomyocytes in culture 
dishes is enabled by the gap junctions, which represent channels connecting two cells.  Two 
types of action potentials were detected in hESC-derived cardiomyocytes, shorter, atrial 
cardiomyocyte-like, and longer, ventricular cardiomyocyte-like.(152)  These data are in 
correlation with another study where we demonstrated the presence of calcium transients in 
hiPSC-derived cardiomyocytes that by their duration corresponded to shorter and longer 
action potentials.(30)  Therefore, these results suggest the presence of functional ion channels 
and transporters in both hESC- and hiPSC-derived cardiomyocytes that are capable of 
maintaining ion gradients across the sarcolemma which are prerequisite to action potentials.  
Moreover, these channels can respond to depolarization stimuli and follow programmed 
patterns of closing and opening in order to generate the action potential, i.e. timely fluxes of 
ions across the sarcolemma.  In functional cardiomyocytes membrane depolarization caused 
by actins potentials is necessary to trigger calcium influx from T-tubules and sarcoplasmic 
reticulum.(153)  Opening of sarcolemmal L-type calcium channels initiates influx of calcium 
that further induces calcium release from the sarcoplasmic reticulum via ryanodine receptor, 
which is called calcium-induced calcium release.(153)  A rise in sarcoplasmic calcium allows 
the interaction among contractile filaments following the binding of calcium to troponin 
complex, which triggers the contraction of the cardiomyocyte.  qPCR and immunostaining 
experiments confirmed the presence of cardiac troponin T in hESC and hiPSC lines.  The 
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presence of calcium transients consisting of calcium influx (corresponding to heart systole) 
and calcium efflux (corresponding to heart diastole) in hiPSC-derived cardiomyocytes was 
shown in our previous study.  This experiment provided the final proof of a proper excitation-
contraction coupling and electromechanical competence of human pluripotent stem cell-
derived cardiomyocytes. 
qPCR experiments verified the presence of several ion channels that are found in 
cardiomyocytes and which underlie the observed excitability and electromechanical 
competence of stem cell-derived cardiomyocytes discussed in the paragraph above.  This 
includes HCN4 (hyperpolarization-activated cyclic nucleotide-gated channel 4), which is a 
sodium and potassium channel found in adult sino-atrial node cells and also in the first heart 
field as a marker of cardiomyogenic progenitors.(154, 155)  Unlike other ion channel genes 
analyzed here that showed greater expression in later phase of cardiac differentiation, HCN4A 
was found to have peak expression in early differentiation (day 6).  A recent study 
demonstrated that maturation of hESC-derived cardiomyocytes is accompanied with increased 
association of HCN4 and caveolin-3, which is thought to be an important step in cardiac 
maturation.(156)  Mutations in this gene have been linked to the sick sinus syndrome, which 
is manifested by arrhythmia, either as bradycardia, or tachycardia or combination of both in 
alternating pattern.(157, 158) 
SCN5A (sodium channel, voltage-gated, type V, alpha subunit) is another sodium 
channel found to be increasingly expressed with cardiac differentiation of hESC and hiPSC 
lines here.  The gene SCN5A encodes Nav1.5, a sodium ion channel subunit., which is 
abundantly expressed in the human atrial and ventricular myocardium.(159)  Opening of the 
channel is responsible for the initial upstroke of the action potential.(159)  Mutations of this 
gene are found in several diseases, including Brugada syndrome, Romano-Ward syndrome, 
sick sinus syndrome and others.(158, 160)  Brugada syndrome is caused by dysfunction of 
several different ion channels, where SCN5A mutation impairs normal actions potentials, 
especially in epicardial areas, leading to lethal ventricular fibrillations.(158)  Romano-Ward 
syndrome is a form of long QT syndromes that predisposes heart to arrhythmia.(160) 
CACNA1C (calcium channel, voltage-dependent, L type, alpha 1C subunit) encodes 
CaV1.2., a subunit of L-type calcium channel found in different cell types, especially in 
cardiac and brain cells.(161)  As described in the chapter 1, opening of this channel leads to 
calcium influx into the cardiomyocyte causing a plateau in the action potential and also 
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initiation interactions among contractile filaments.  The experiments presented here showed a 
progressive increase in the expression of this channel in all four lines, indicating its important 
role in the mature heart cells.  The mutation of this gene causes Timothy syndrome that 
affects many parts of the body and causes long QT syndrome.(162, 163)  Cardiac dysfunction 
in Timothy syndrome is characterized by prolonged calcium influx with arrhythmia and 
cardiac malformations.(162) 
All three analyzed potassium channels KCNH2 (potassium voltage-gated channel, 
subfamily H (eag-related), member 2), KCNJ2 (potassium inwardly-rectifying channel, 
subfamily J, member 2) and KCND3 (potassium voltage-gated channel, Shal-related 
subfamily, member 3) exhibited a tendency for a stabile increase in the expression with 
cardiomyocyte maturation.  KCNH2 is found in cardiomyocytes, neurons and microglia.(164)  
In excitable cells, channel made from alpha KCNH2 subunits is responsible for repolarization 
after initiation of the action potential.(160, 164)  Mutations of this gene have been described 
in Romano-Ward syndrome, short QT syndrome and other diseases.(165)  KCNJ2 is 
expressed in cardiac and skeletal muscle and is also responsible for cell repolarization.(166)  
Mutations are associated with Andersen-Tawil syndrome, short QT syndrome and familial 
atrial fibrillation.(166, 167)  Andersen-Tawil syndrome is one of the subtypes of long QT 
syndromes.  KCND3 is expressed in variety of cells, including cardiomyocytes.  Its 
dysfunction is associated with lethal ventricular arrhythmias.(168)  qPCR experiments 
demonstrated the presence of sodium, potassium and calcium channels that play the critical 
role in generation of action potentials and calcium influx and are principal structures that 
mediate observed action potentials and contractions in our human pluripotent stem cell-
derived cardiomyocytes.  Altogether, cell beating, action potentials and expression of cardiac 
ions channels indicates electromechanical competence of human pluripotent stem cell-derived 
cardiomyocytes tested in this dissertation. 
Contractile machinery in cardiomyocytes.  Regular beating pattern of cell clusters in 
all four lines, hESC and hiPSC, suggested the presence of the functional contractile 
machinery in these cells, which was verified with immunostaining experiments.  Laser-
scanning confocal microscopy allowed examination of sarcomeres with a high spatial 
resolution.  Regular striated pattern was observed for two tested sarcomeric proteins, 
sarcomeric α-actinin and cTnT in all hESC and hiPSC lines.  cTnT is found solely in 
cardiomyocytes, while sarcomeric α-actinin is less specific and is expressed in the Z lines of 
skeletal and cardiac muscle(150).(169)  Additional testing was performed in H1 line for 
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myofilament proteins, titin and MLC 2a (myosin light chain 2a) which corroborated these 
results, i.e. they were also expressed in the striated pattern.  Our results are in agreement with 
other studies showing enhanced expression of MLC 2v and MLC 2a and other sarcomeric 
proteins in a striated pattern in cardiomyocytes differentiated from human pluripotent stem 
cells.(170)  
Extensive analysis of myofilament gene expression at various stages of 
cardiomyogenesis supported immunostaining experiments.  A progressive increase in the 
expression with cardiac maturation was found for most of the tested genes.  TNNT2 (troponin 
T type 2, cardiac) is normally found solely in the heart where it regulates the intensity of 
interaction of actin and myosin filaments and thereby heart contractility.  The results 
presented here show continuous increase in the expression of this gene as it was expected due 
to cardiomyocyte maturation.(171)  Both hESC lines exhibited greater expression of TNNT2 
than the hiPSC lines in later stages of cardiomyogenesis, which is in correlation with the 
observation that differentiation of hESC lines yielded greater number of contracting areas.  
Mutations in this gene are found in familial hypertrophic cardiomyopathy.(172)  MYL7 
(myosin light chain 7), another contractile protein, was predominately expressed in a later 
phase of differentiation only in hESC lines, while in hiPSC lines its expression was increased, 
but steady throughout cardiomyogenesis.  As for TNT2, MYL7 was also more expressed in 
hESC lines than hiPSC lines in later stages of cardiomyogenesis. 
The obtained results are in agreement with a previously published whole-genome 
microarray analysis conducted in a hESC subjected to cardiomyogenic directed differentiation 
over a period of 12 days showing an increase in the expression of TNNT2, MYL7 and other 
myofilament genes.(171)  The same study presented similar results when gene expression 
analysis was performed in human fetal heart obtained from voluntary abortion.  This was an 
important finding since it demonstrated that human stem cell-derived cardiomyocytes exhibit 
similar gene expression pattern as the human fetal heart.  
Genetic labeling of living cardiomyocytes.  Although directed differentiation yields 
high percentage of cardiomyocytes, other cell types are also present in these culture dishes.  In 
this dissertation, cell were genetically labeled with the reporter construct MLC 2v-EGFP that 
is expressed only in cardiac cells in order to conduct experiments only on cardiomyocytes.  
Following the directed differentiation and prior to experiments, cells were enzymatically 
dissociated and transduced with the lentiviral vector carrying MLC 2v-EGFP construct.  This 
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construct allowed the expression of EGFP (that is detected by green fluorescence) only in 
cells that have cardiac specific promoter MLC 2v.  Such approach has been previously used in 
Dr. Gepstein’s laboratory to identify differentiated cardiomyocytes and the same group 
provided the MLC 2v-EGFP construct for our experiments.(138)  The identification of 
cardiomyocytes with this approach is particularly useful as it allows identification of living 
cells that can be subsequently used for experimentation. 
 
Cardiomyogenesis in hESC vs. hiPSC lines 
We simultaneously compared the cardiomyogenic potential of two human iPSC lines 
with two well-characterized human ESC lines, under controlled conditions using a directed 
differentiation protocol.  We show that cells from all four pluripotent stem cell lines can 
differentiate toward a cardiomyocyte fate.  However, H1 ESCs exhibited the most overt 
cardiomyogenic competence, forming extensive areas of rhythmically contractile cells 
(Supplemental Video Clips 1-4 in reference (136)) that contained organized sarcomeres 
(Figure 3).  Accordingly, in terms of biochemical differentiation, H1 cells from both beating 
and non-beating areas of the culture dish expressed the highest percentage of EGFP-positive 
cells (Figure 13), and, qPCR revealed that H1 cells were the most robust in terms of 
cardiomyogenic gene expression (Figure 14).   
Several groups have reported that human and mouse iPSCs possess cardiomyogenic 
competence.(173-178)  Among these findings, those of Zhang et al. (178) are particularly 
noteworthy because these investigators compared differentiation of H1 and H9 ESCs with two 
lines of lentivirus-induced human iPSCs, observing that sarcomere organization and 
expression of cardiomyogenic genes were indistinguishable in iPSCs and ESCs although the 
ability to contract was highest in H9 ESCs.  Despite similarities in approach it is difficult to 
compare these findings with those described here since Zhang et al. (178) used an EB rather 
than a directed differentiation format, and because their gene expression analysis was based 
on a single endpoint determination.  Regarding competence of H1 and H9 ESCs, differences 
in cardiomyogenic potency have previously been noted, attributed to epigenetic marks;(179, 
180) reports now indicate that the most cardiomyogenic ESC line is either H1 (this paper and 
(137)), or H7 (20), or H9 (178).  These differences are possibly related to differences in 
spontaneous differentiation that were noted during pluripotent expansion and passaging of the 
cell-lines used in this study.  Specifically, spontaneous differentiation in H1 ESCs was 
minimal during more than 50 passages, in contrast with H9 ESC colonies which exhibited 
differentiation after only seven passages.  Both iPSC lines displayed even greater propensity 
62 
 
to spontaneously differentiate, requiring the establishment of fresh colonies after every fourth 
passage.  Although epigenetic factors may have influenced these results, differences in cell 
culture format and induction conditions, for example directed differentiation vs. the EB 
format, certainly effected differentiated outcomes.  Hence, while the results described here 
indicate that both of the ESC and iPSC lines can enter the cardiomyogenic pathway but that 
only the ESC lines exhibited substantial terminal differentiation, such a conclusion must 
remain tentative until universal conditions are established to efficiently, reproducibly and 
rapidly induce pluripotent cells to defined terminally differentiated cardiomyogenic 
endpoints. 
Regarding the relative inability of C2a and C6a iPSCs to develop into functional 
cardiomyocytes, the possibility that differentiation is suppressed due to the integration of 
pluripotency genes in lentivirus-induced iPSCs was previously noted.(178)  However, the 
decline of OCT4 expression in C2a and C6a cells was essentially equivalent to that observed 
in H1 and H9 ESCs (Figure 14).  Moreover, evidence that C2a iPSCs are differentiation-
competent was recently demonstrated by the equivalent ability of C2a iPSCs and H9 ESCs to 
undergo growth factor-directed differentiation into mature hepatocytes, with efficiency 
exceeding 80%.(10)  Although the relative inability of iPSCs to undergo terminal myocyte 
differentiation is unexplained, it is noted that the highly efficient differentiation of 
hepatocytes was performed in monolayer culture format wherein all cells are exposed to 
equivalent growth factor levels, in contradistinction to the induction of pluripotent cells 
organized in three-dimensional clumps as employed here.  It is therefore speculated that the 
relative inability of iPSCs to terminally differentiate may indicate that while initial 
cardiomyogenic signals in clumped cells were sufficient to overcome the presence of 
integrated pluripotency genes, signals that regulate terminal differentiation were somehow 
compromised.  It is nonetheless encouraging that most C2a and C6a cells, whether derived 
from beating or non-beating areas, exhibited activation of transduced MLC 2v (Figure 13), 
suggesting that these cells occupy a position in the cardiomyogenic pathway from which 
improved signaling may support terminal differentiation.  In this regard we are currently 
inducing pluripotent cells maintained in monolayer culture, with the goal of establishing 
conditions that mimic the high levels of efficiency that are reproducibly achieved during 
hepatocyte differentiation.(10) 
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APC in human pluripotent stem cell-derived cardiomyocytes. 
The results discussed so far demonstrate that hESC- and hiPSC-derived 
cardiomyocytes reconstitute crucial steps in cardiomyogenesis and that they exhibit key 
functions characteristic for adult cardiomyocytes, i.e. they form syncytium and synchronously 
beat in the culture dish.  In the subsequent series of experiments it was tested whether human 
pluripotent stem cell-derived cardiomyocytes have developed competent endogenous 
mechanisms that can be elicited by the APC and which afford protection against the oxidative 
stress, a hallmark of reperfusion injury. 
 We showed here that isoflurane partly depolarized mitochondria in a 5-HD-
sensitive manner, suggesting opening of mitoKATP channels, crucial mediators of 
cardioprotection.(97, 111)  This effect was almost identical to isoflurane-induced opening of 
mitoKATP channels demonstrated with the similar approach in our previous study using adult 
rat cardiomyocytes,(111) indicating a comparable response between adult and hESC-derived 
cardiomyocytes.  We also showed here that isoflurane moderately enhanced production of 
ROS, an important component of preconditioning signaling cascade.(52, 112)  Our previous 
study demonstrated that desflurane and sevoflurane induce similar extent of ROS production 
in adult rat cardiomyocytes.(52)  The importance of ROS was confirmed here by showing that 
a low dose of H2O2 induces preconditioning and delays mPTP opening, which is in agreement 
with a study by Hanouz et al. that indicated critical importance of ROS signaling in APC 
using adult human atrial trabeculae.(145)  Anesthetic-induced increase in ROS production has 
been attributed to the opening of mitoKATP channels,(112) but it can be also induced by partial 
obstruction of the ETC,(181) another effect of volatile anesthetics.(109)  Indeed, in this study 
we showed that isoflurane induces partial obstruction of the ETC, indicated by attenuation of 
oxygen consumption in beating cell clusters by isoflurane.  This effect is similar to our results 
obtained in adult rat cardiomyocytes using identical approach, which we correlated to the 
ETC inhibition.(104)  The importance of mitoKATP channel opening for inducing 
cardioprotection by APC was verified here by showing that inhibition of channel opening by 
5-HD abrogates the APC-induced delay in mPTP opening. 
In chapter 5 it was shown that volatile anesthetic isoflurane inhibits oxygen 
consumption of isolated beating cell clusters that have high hESC-derived cardiomyocyte 
enrichment.  This result is in a good correlation with our previous study demonstrating similar 
effect in adult rat cardiomyocytes.(104)  In that study, an extensive investigation including 
non-permeabilized cells and isolated mitochondria demonstrated that observed inhibition of 
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respiration originated from the partial inhibition of the complex I of the respiratory chain by 
isoflurane.  This finding is also verified by other studies.(109)  It has been shown that the 
partial inhibition of complex I, for example with rotenone, increases generation of ROS.(110)  
A partial inhibition of the complex I of the respiratory chain disrupts the normal electron flow 
within the complex increasing electron leak at the complex I.  Resulting incomplete reduction 
of oxygen molecule by a single electron at the complex I yields a superoxide anion (O2
•).(44, 
182)  Normally, during oxidative phosphorylation, two electrons reduce a single oxygen 
molecule yielding water at the complex IV.  These experiments suggested that partial 
complex I inhibition by isoflurane may result in a moderate increase in ROS production that 
in turn triggers preconditioning signaling cascade.  Indeed, results shown in Figure 8 verified 
that clinically relevant concentration of isoflurane (0.5 mM, corresponding to 1 minimal 
alveolar concentration) moderately increased production of ROS in hESC-derived 
cardiomyocytes.  The importance of this moderate increase in ROS production is best 
demonstrated in a study showing that elimination of this signaling ROS by ROS scavenger 
Trolox completely blocked preconditioning by two volatile anesthetics sevoflurane and 
desflurane.(52)  Several other studies also showed that ROS scavenging during triggering 
phase of either ischemic preconditioning or isoflurane-induced APC blocks 
cytoprotection.(183-185)  Although it may seem paradoxical that ROS exerts beneficial effect 
for protecting cells from oxidative stress and ischemia-reperfusion injury, it is now known 
that moderate amount of stress in the form of ROS serve as the crucial signal that initiates 
preconditioning and prepares the cell for upcoming greater amounts of oxidative stress 
occurring in the reperfusion.  This was verified by the experiment in this dissertation showing 
that small amounts of exogenous H2O2 triggered preconditioning and protected cells from the 
excessive amounts of oxidative stress causing cell death.  Downstream targets of this 
signaling ROS that have been identified so far include PKC and the hypoxia-induced factor-
1alpha (HIF-1α) in cancer cells.(113, 186)   
In the chapter 5 it was also shown that isoflurane depolarizes mitochondria, which was 
attenuated by inhibition of mitoKATP channels with 5-HD, and which was mimicked by 
mitoKATP channel opening with diazoxide.  This finding indicated that isoflurane induced 
opening of mitoKATP channels, which was previously shown in many studies to be important 
event for preconditioning.(95, 97, 111, 112)  Opening of the mitoKATP channels plays a 
significant role both in the triggering phase of preconditioning, and as an effector of 
cytoprotection.(97)  In the triggering phase, opening of the mitoKATP channels may contribute 
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to enhanced ROS production, which augments preconditioning stimulus by stimulating the 
flux of electrons along the respiratory chain and thereby electron leak.  Studies showed that 
mitoKATP channels remain open during the memory phase of preconditioning and attenuate 
ischemia-reperfusion injury by decreasing mitochondrial calcium overload, which is one of 
potent inducers of mPTP opening.(111, 126)  Partial inhibition of the respiratory chain with a 
moderate increase in ROS production and opening of mitoKATP channels are fundamental 
events required for eliciting cytoprotective pathways.  The obtained results are well matched 
with previous results and indicate that APC elicits adequate signals in hESC-derived 
cardiomyocytes. 
The final proof of effectiveness of APC in human pluripotent stem cell-derived 
cardiomyocytes were experiments with the mPTP opening and the cell survival.  Our results 
indicated that preconditioning with isoflurane induced a delay in opening of the mPTP both in 
hESC- and hiPSC-derived cardiomyocytes.  Preconditioning with 0.5 mM isoflurane 
increased the arbitrary mPTP opening time compared to control in hESC-derived 
cardiomyocytes exposed to photoexcitation-generated oxidative stress.  This indicated that 
APC elicited innate mechanisms that increased the threshold for mPTP opening.  It has been 
shown before that cardioprotective treatments increase the amount of stress required for 
induction of mPTP opening.(80, 102)  This has a significant functional importance since the 
opening of mPTP has been recognized as the crucial event in the transition towards cell death 
during I/R injury.(42).  Moreover, mPTP inhibition reduces infarct size in vivo.(133, 134) 
Cardioprotective strategies, including APC were found to induce delay in mPTP opening and 
mPTP blockers may decrease infarct size by 30-50%.(187)  This is in correlation with the 
observed delay in mPTP opening by mPTP inhibitor cyclosporine A, as shown in Figure 9 
here.   
Inhibition of mitoKATP channel opening abrogated APC, while preconditioning with 
the exogenous H2O2 delayed mPTP opening.  These experiments verified an important role of 
mitoKATP channels and small amounts of ROS for induction of cytoprotection by APC in 
hESC-derived cardiomyocytes.  Animal in vivo experiments show that inhibition of mitoKATP 
channels by 5-HD abrogates APC,(112) while preconditioning with diazoxide, a mitoKATP 
channel opener reduces infarct size.(188)   
During I/R, opening of mPTP dissipates ∆Ψm, preventing oxidative phosphorylation 
and initiates death pathways in the cell.(42)  Using an identical approach as in this 
dissertation, we previously demonstrated that APC induces a similar delay in mPTP opening 
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in adult rat cardiomyocytes,(102) which further correlates with another study from our 
laboratory demonstrating that APC elicits cellular and mitochondrial protective mechanisms 
against oxidative stress in human adult cardiomyocytes.(100)  The inhibition or the delay in 
mPTP opening is associated with improved cell survival since mPTP opening is a critical step 
in the initiation of apoptotic and necrotic death pathways.(56, 57, 64, 126, 189)  Inhibition of 
mPTP opening can postpone cell death pathways by preventing the release of 
intramitochondrial proteins, such as apoptosis-inducing factor (AIF), or by preventing the 
rupture of outer mitochondrial membrane and the release of proapoptotic cytochrome c, or by 
delaying cessation of ATP production that is accelerated with the collapse of ∆Ψm due to 
mPTP opening.(126)  It is also shown here that APC induced the delay in mPTP opening in 
hiPSC-derived cardiomyocytes, suggesting existence of equivalent cytoprotective 
mechanisms in hESC-derived cardiomyocytes and hiPSC-derived cardiomyocytes.  A strong 
correlation between mPTP opening and cell death was confirmed with cell survival 
experiments in Figure 5 showing that APC-induced delay in mPTP opening is paralleled with 
a decrease in the number of dead hESC-derived cardiomyocytes exposed to oxidative stress.  
This was another proof that hESC-derived cardiomyocytes have developed competent 
cytoprotective machinery that protects cells against oxidative stress in a similar fashion as in 
adult cardiomyocytes freshly isolated from the rat heart. 
Taken altogether, all tested parameters indicate similar responses of adult 
cardiomyocytes and hESC-derived cardiomyocytes to APC. 
Studies using hESC-derived cardiomyocytes to regenerate dysfunctional myocardium 
after I/R injury have had limited success due to factors including inefficient differentiation, 
poor engraftment and survival within injured myocardium.(190)  However, Laflamme et al. 
demonstrated that the use of a pro-survival cocktail during implantation of hESC-derived 
cardiomyocytes improved cell engraftment and functional recovery of the heart.(5)  This 
cocktail protected graft cells from the stressful environment of (post)ischemic myocardium by 
blocking cellular death pathways.  Interestingly, APC involves inhibition of the same cellular 
death pathways as pro-survival cocktail.(102, 103, 112)  This suggests that APC could 
improve cardiomyocyte engraftment, with the added advantage that, unlike the components of 
the cocktail, volatile anesthetics are approved for the clinical application.  In fact, the recent 
Guidelines by the American College of Cardiology and the American Heart Association 
recommended the use of volatile anesthetics based on the findings of 15 randomized trials in 
patients undergoing coronary bypass surgery showing that volatile anesthetics decrease 
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cardiac troponin release and improve ventricular function in comparison with intravenous 
anesthetics.(99) 
 
Relevance of the doctoral dissertation and prospects 
The key scope of this dissertation proposal is to contribute to the development and the 
use of human pluripotent stem cell-derived cardiomyocytes, especially hiPSC-derived 
cardiomyocytes for investigation of APC.  Preconditioning by volatile anesthetics is a 
clinically applicable therapy that may ameliorating cardiac ischemia-reperfusion injury.(99)  
Human cell models based on the differentiation from stem cells have been recognized as an 
attractive approach for studying many other disease models based on different cell types.(6, 
31, 33, 38, 39)  Therefore, this dissertation, by showing feasibility of utilizing human stem 
cell models for testing APC will also aid and encourage the use of this approach for studying 
other diseases.  The current process of new drug discovery is relatively expensive and lengthy 
in part due to inefficient translation of findings from animals to human subjects.(6)  Human 
stem cell-based models hold a great promise in upgrading translational research with a 
“clinical trial in a dish” approach.(6)  Along these lines, Dr. Collins stated: “The use of animal 
models for therapeutic development and target validation is time consuming, costly, and may 
not accurately predict efficacy in humans.”  He sees the solution in: “more reliable efficacy 
models that are based on access to biobanks of human tissues, use of human embryonic stem 
cell and induced pluripotent stem cell models“.  Thus, by contributing to new trends for 
accelerating and advancing translational research, this dissertation may have an important 
impact on people’s health and pharmaceutical industry.  Other investigators have 
demonstrated that hESC- and hiPSC-based models reliably recapitulate certain normal and 
disease phenotypes, including “cerebral organoids” as a 3D model of early brain development 
or long QT syndrome cardiac model exhibiting electrophysiological properties characteristic 
for cardiomyocytes of patients with the disease.(33, 39)   
hiPSC models are of particular value for disease modeling since these cells carry 
identical genotype as the person who donated skin fibroblasts or other cells for 
reprogramming.  This can be exploited in a sense that by selecting patients with specific 
disease with genetic component, derived hiPSC lines and differentiated cells exhibit 
phenotypic characteristics driven by the disease genotype (Figure 1).  This provides a unique 
opportunity to dissect genetic and environmental factors of that disease using a cell model in a 
highly controlled experimental environment.  Based on the ground work laid by this 
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dissertation, our group has already utilized diabetic hiPSC-derived cardiomyocytes to study 
underlying mechanisms of inefficient APC in a diabetic heart.(191)  This pioneering 
manuscript has demonstrated for the first time that both genetic and environmental factors 
(high glucose) interfere with APC in diabetic cardiomyocytes.  Although in humans we can 
correlate genes with diseases like type 2 diabetes mellitus, our understanding of phenotypic 
significance, mechanistic aspects and quantitative nature of pathological processes related to 
identified genes requires experimental perturbations that are almost exclusively performed in 
animal models.  Since animal models cannot consistently emulate human (patho)physiology, 
hiPSC-derived cardiomyocytes would allow phenotypic characterizations circumventing ever-
present issue of species differences.  hiPSC-derived cardiomyocyte would allow not only to 
distinguish contribution of genetic and environmental factors to inefficient preconditioning in 
diabetics, but they allow us to “rescue” preconditioning by overexpressing or silencing genes 
of interest.  hiPSC-derived cardiomyocytes can widen our perspectives in studying absence of 
cardioprotection by APC in diabetics.  This aspect of future use of the hiPSC-derived 
cardiomyocyte model is epidemiologically and clinically very important.  On one hand, the 
incidence of diabetes mellitus is increasing.  On the other hand, clinical reports show that 
cardiovascular incidents like myocardial infarction are particularly severe in diabetics,(192) 
while APC is ineffective in animal models of ischemia-reperfusion injury.(193)  Due to 
limited availability of human subjects and materials for research purposes and the use of less 
reliable animal models, mechanisms by which diabetes and other factors modify 
preconditioning are not completely understood.  Extensive studies are required to identify 
defective pathways of APC in human diabetic myocardium in order to design targeted 
therapy.  hiPSC-derived cardiomyocytes seem as a new promising tool in this quest, and in 
other clinically relevant problems, such as ageing, where APC is ineffective or requires 
improvements. 
Cardioprotection by APC has been first described in 1988 at the Department of 
Anesthesiology, MCW, two years after initial discovery of ischemic preconditioning by 
Murry and colleagues.(194)  These cardioprotective properties of volatile anesthetics have 
been recognized and promoted in the Guidelines of the American College of Cardiology and 
the American Heart Association, which is the best indicator of relevance of APC for clinical 
practice.(99)  Modulation of myocardial infarct size by pharmacological agents either as 
preconditioning or postconditioning strategies are potentially very valuable for clinical 
practice.  
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7. CONCLUSION 
 
Several lines of evidence were presented in this dissertation to support the hypothesis 
that human pluripotent stem cell-derived cardiomyocytes exhibit similar responses to APC as 
adult animal cardiomyocytes and human myocardium and represent a feasible model for 
studying APC in human cell model in vitro: 1) directed differentiation yields high percentage 
of cardiomyocytes both in hESC and hiPSC lines, 2) cardimyogenesis in hESC and hiPSC 
lines recapitulates temporal gene expression profile seen in normal cardiac differentiation, 3) 
differentiated cardiomyocytes are excitable cells that exhibit functional contractile machinery 
and are capable of performing regular contractions, 4) volatile anesthetic isoflurane elicits 
crucial mediators of preconditioning signal transduction pathways and effectors of 
cytoprotection in human pluripotent stem cell-derived cardiomyocytes resulting in improved 
cell resistance to oxidative stress.  Thereby, it can be concluded that human pluripotent stem 
cell-derived cardiomyocytes can be used for studying mechanisms of APC in vitro.  This can 
be used as a new complementary experimental model that may accelerate translation of results 
obtained in basic research to clinical practice. 
We showed that hESC-derived cardiomyocytes phenotypically resemble functional 
human cardiomyocytes by showing that these cells spontaneously and rhythmically contract, 
generate action potentials that, by shape and morphology resemble functional human 
cardiomyocytes.  Moreover, these cardiomyocytes exhibit highly organized sarcomeric 
structures, indicated by immunostaining for cardiac-specific cTnT and MLC 2a and non-
specific sarcomeric α-actinin and titin.  This is in accord with other laboratories that have 
described structural properties of hESC-derived cardiomyocytes.(150, 195, 196)  The 
presence of spontaneously and rhythmically beating cell clusters that extend throughout the 
culture dishes (please see link: http://links.lww.com/ALN/A624), indicate presence of 
cardiomyocytes that form a functional syncytium which exhibits synchronized action 
potential propagation.(150, 197) Other laboratories demonstrated electrophysiological and 
functional competence of hESC-derived cardiomyocytes by electrophysiological recordings, 
measurements of Ca2+ transients, as well as appropriate chronotropic responses to β- and 
muscarinic receptor stimulation.(150, 195, 197-201)  However, the extent of these cells’ 
maturity requires further investigation.(190)  At minimum, studies describe hESC-derived 
70 
 
cardiomyocytes as cells having characteristics of embryonic cardiomyocytes that may, with 
extended time in culture, differentiate into a mature cardiomyocyte phenotype.(202) 
We have demonstrated molecular mechanisms by which preconditioning with 
isoflurane elicits competent defense against oxidative stress in hESC-derived cardiomyocytes.  
These protective mechanisms have been previously characterized in our and other laboratories 
using animal (52, 102, 103, 111) and, to lesser extent, human myocardium.(100, 145)  
However, it was unclear whether hESC-derived cardiomyocytes have adequate phenotype to 
resist oxidative stress, a hallmark of I/R injury.(41)  In this study, we showed that APC 
successfully protects hESC-derived cardiomyocytes from oxidative stress, which is in 
accordance with the results of our previous study using adult human atrial 
cardiomyocytes.(100)  To investigate the phenotypic similarity of the cardioprotective 
mechanisms by APC between adult cardiomyocytes and hESC-derived cardiomyocytes, we 
tested some of the most relevant mediators of protection.   
In conclusion, our study shows for the first time that preconditioning with anesthetic 
isoflurane elicits competent defensive mechanisms against oxidative stress in ventricular 
hESC-derived cardiomyocytes.  A similar APC-induced delay in mPTP opening in hESC- and 
hiPSC-derived cardiomyocytes suggested existence of similar cytoprotective mechanisms in 
both hESC-derived cardiomyocytes and hiPSC-derived cardiomyocytes.  The similarity in 
responses to APC between adult cardiomyocytes documented in our previous work and 
hESC-derived cardiomyocytes demonstrated here implies that these cardiomyocytes can be 
used as a valuable experimental human model to study APC, and possibly other human 
diseases/treatments.  As a complimentary model of human cardiomyocytes, hESC-derived 
cardiomyocytes offer new experimental advantages, overcoming previous limitations when 
using human myocardium from patient surgeries.  Moreover, APC may be a promising tool 
for protecting hESC-derived cardiomyocytes during engraftment, thereby increasing 
regeneration of injured myocardium.  Importantly, our study also demonstrates a simple and 
efficient modification of previously published protocols to differentiate human 
cardiomyocytes from hESCs. 
Although biochemical evidence of cardiomyogenesis was similar in all four hESC and 
hiPSC lines, terminal differentiation into cardiomyocytes exhibiting well-defined sarcomeres 
and rhythmic contractions was most pronounced in H9, and especially in H1 ESCs.  However, 
a considerable cardiomyocyte enrichment obtained in hiPSC lines suggests feasibility of using 
these cells for in vitro testing of APC.  
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8. ABSTRACT OF DISSERTATION 
 
The lack of human myocardium for research purposes represents a great problem in 
studying pathogenesis of human cardiac disease.  The doctoral dissertation is designed to test 
whether cardiomyocytes differentiated from human pluripotent stem cells can be used for 
studying anesthetic preconditioning (APC), a cardioprotective strategy.  Human embryonic 
stem cell (hESC) lines, H1 and H9, and human induced pluripotent stem cell (hiPSC) lines, 
C2a and C6a were differentiated into cardiomyocytes by directed differentiation.  All 
experiments with hESCs were conducted at the Medical College of Wisconsin using 
commercially available lines and their use was approved by the local Ethical Committee.  
hiPSC were obtained from the laboratory of Dr. S.A Duncan, MCW.  Cardiac differentiation 
of hESC and hiPSC lines was accompanied with the occurrence of spontaneous contractions 
in cell clusters.  Cardiac enrichment was greater than 65% in beating clusters of all cell lines.  
Living differentiated cardiomyocytes were labelled with a genetic construct, MLC 2v-EGFP, 
delivered by a lentiviral vector.  Immunostaining for sarcomeric proteins, sarcomeric-α 
actinin and cardiac troponin T revealed that sarcomeres in hESC- and hiPSC-derived 
cardiomyocytes exhibited a proper striated pattern.  The time course of expression of genes 
involved at various stages of cardiomyogenesis was analyzed by qPCR in all hESC and hiPSC 
lines.  It revealed that the loss of expression of pluripotency and later mesodermal gene was 
accompanied by the increase in expression of genes of early phase of cardiac differentiation.  
Genes characteristic for terminal cardiac differentiation were expressed during the second 
week of cardiomyogenesis.  APC of hESC- and hiPSC-derived cardiomyocytes induced a 
delay in opening of the mitochondrial permeability transition pore (mPTP) in stressed cells, 
which is a critical mediator of protection by APC.  Increase in the survival of preconditioned 
cardiomyocytes correlated with the delay in mPTP opening in hESC-derived cardiomyocytes. 
Isoflurane activated characteristic mediators of preconditioning in hESC-derived 
cardiomyocytes.  It induced opening of mitoKATP channels and moderately increased 
production of reactive oxygen species by inhibiting respiratory chain. 
In conclusion, functional human pluripotent stem cell-derived cardiomyocytes can be 
efficiently differentiated in vitro.  These cells exhibit competent responses to APC and 
therefore could be used as a reliable experimental models for studying APC. 
Keywords: human pluripotent stem cells, differentiation, cardiomyocytes, anesthetic 
preconditioning, reactive oxygen species, mitochondrial permeability transition pore. 
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SADRŽAJ DISERTACIJE 
Uvod:  Postoje brojne prepreke u translacijskim istraživanjima i njihovoj sigurnoj i efektivnoj 
kliničkoj primjeni, kao što je upotreba animalnih modela koji su skupi, zahtijevaju velik 
utrošak vremena i ne mogu predvidjeti točan odgovor u ljudi.  Ipak, istraživanja koja testiraju 
učinke lijekova i patogenezu brojnih patoloških stanja i bolesti, uključujući i bolesti srca, se 
većinom provode na životinjskim modelima i zahtijevaju ocjenu valjanosti na ljudskim 
modelima.  Priznate alternative su ljudski modeli dobiveni iz banaka ljudskog tkiva, ljudske 
embrionalne matične stanice (hESC) i ljudske inducirane pluripotentne matične stanice 
(hiPSC).  Anesteticima-potaknuto prekondicioniranje (APC) je strategija koja potiče 
endogene zaštitne mehanizme u stanicama srca koji mogu povećati preživljenje ovih stanica 
tijekom ishemijsko-reperfuzijske ozljede.  Doktorska disertacija je osmišljena kako bi se 
testiralo mogu li se ljudske pluripotentne matične stanice diferencirati u kardiomiocite koji bi 
se koristili kao eksperimentalni model za istraživanje APC-a. 
Materijali i metode:  Predložena disertacija se bazira na istraživanjima provedenim na dvije 
vrste ljudskih pluripotentnih matičnih stanica, i to na hESC linijama i hiPSC linijama.  
Prethodno je pokazano da se ove pluripotentne matične stanice mogu diferencirati u derivate 
svih triju embrionalnih zametnih listića, uključujući i kardiomiocite.  U istraživanju se 
koristilo komercijalno dostupne hESC linije, H1 i H9, a eksperimenti su se izveli na Medical 
College of Wisconsin-u uz odobrenje lokalnog etičkog povjerenstva. hiPSC linije su dobivene 
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iz laboratorija dr. S. Duncana.  Ove stanice su generirane iz fibroblasta kože prepucija nakon 
transdukcije s čimbenicima OCT4, NANOG, SOX2 i LIN28.  Pokazano je da ekspresija tih 
proteina uzrokuje dediferencijaciju već diferenciranih fibroblasta u pluripotentno stanje. 
Laboratorij dr. Duncana je potvrdio sve karakteristike pluriopotentnosti ovih stanica i pokazao 
da se mogu efikasno diferencirati u hepatocite.  Kardiomiociti su diferencirani iz 
pluripotentnih stanica metodom usmjerene diferencijacije.  Da bi se eksperimenti provodili 
isključivo na kardiomiocitima stanice su se obilježile zelenim flourescentnim proteinom 
(EGFP) pod transkripcijskom kontrolom gena za miozinski laki lanac 2v (MLC 2v) koji je 
specifičan za srčane stanice.  Ovakvo obilježavanje se provelo nakon usmjerene 
diferencijacije tako da su stanice bile transducirane lentiviralnim vektorom koji sadrži 
MLC2v-EGFP konstrukt.  Ovaj konstrukt omogućuje da EGFP (koji se detektira zelenom 
fluorescencijom) bude izražen samo u stanicama koje istovremeno imaju i MLC-2v 
transkripcijski čimbenik, odnosno u kardiomiocitima.  Lentiviralni vektor je dobiven iz 
laboratorija dr. F. Parka, Medical College of Wisconsin.  Svi eksperimenti u kojima se 
koristio ovaj virus su provedeni na Medical College of Wisconsin-u.  Kardijalna 
diferencijacija se testirala imunocitokemijskom detekcijom sarkomerskog α-aktinina, 
kardijalnog troponina T i titina.  U disertaciji se testiralo mogu li diferencirani kardiomiociti 
odgovarati na APC na isti način kao i zreli kardiomiociti, a dobiveni podatci su se usporedili s 
rezultatima prethodnih studija.  Ispitalo se nekoliko dobro okarakteriziranih i značajnih 
komponenti APC-a.  Testiralo se može li APC povećati preživljenje kardiomiocita 
diferenciranih iz hESC nakon izlaganja oksidativnom stresu koji je induciran uz pomoć 
vodikovog peroksida.  Zatim se testiralo ima li inhalacijski anestetik izofluran, koji potiče 
APC, utjecaja na proizvodnju slobodnih kisikovih radikala, što je izmjereno u hESC-
diferenciranim kardiomiocitima uz pomoć fluorescentnog indikatora dihidroetidina i 
konfokalnog mikroskopa.  Važni izvršitelji kardioprotekcije APC-om su također testirani.  
Ovo uključuju otvaranje ATP-ovisnih kalijevih kanala u mitohondrijima (mitoKATP) i odgodu 
u otvaranju mitohondrijske permeabilizacijsko-tranzicijske pore (mPTP). Otvaranje mPTP-a 
je inducirano oksidativnim stresom a detektirano je mjerenjem brze i potpune depolarizacije 
mitohondrija konfokalnim mikroskopom uz pomoć fluorescentnog indikatora TMRE.  
Kvantitativni PCR se koristio da određivanje izražaja gena koji su značajni u različitim 
stadijima kardijalne diferencijacije.  Potrošnja kisika u izoliranim nakupinama diferenciranih 
kardiomiocita je mjerena uz pomoć Clarkove elektrode, što se koristilo za ispitivanje protoka 
elektrona kroz respiratorni lanac i neizravno za procjenu moguće opstrukcije respiratornog 
lanca od strane izoflurana. 
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Rezultati: Usmjerena diferencijacija rezultira je visokim udjelom kardiomiocitima u 
dijelovima koji spontano i ritmično kucaju, pri čemu je najviše kardiomiocita detektirano u 
H1 hESC liniji (85%). U ostalim linijama taj broj se kretao oko 65%.  Kardiomiociti su 
izražavali sarkomerične proteine, kardijalni troponin T, sarkomerični α-aktinin i titin.  U 
hESC-kardiomiocitima su detektirani akcijski potencijali koji morfološki odgovaraju zrelim 
ventrikularnim i atrijskim srčanim stanicama.  APC u hESC-kardiomiocitima potiče 
protektivne mehanizme što se očitovalo poboljšanim preživljenjem nakon izlaganja 
oksidativnom stresu te odgođenim otvaranjem mPTP-a.  mPTP je ključni događaj koji inicira 
različite puteve koji dovode do smrti stanice  Pokazano je da izofluran djelomično inhibira 
respiratorni lanac u hESC-kardiomiocitima što dovodi do umjerenog porasta u proizvodnji 
kisikovih radikala koji igraju ključnu ulogu u unutarstaničnoj signalizaciji tijekom 
prekondicioniranja.  Izofluran je doveo i do otvaranja mitoKATP kanala, koji je također važan 
medijator prekondicioniranja. APC je odgodilo otvaranje mPTP-a i u hiPSC-kardiomiocitima.  
Kvantitativni PCR je pokazao da usmjerena diferencijacija dovodi do sličnog obrasca izražaja 
različitih gena tijekom diferencijacije hESC i hiPSC linija.  Pokazano je da tijekom 
diferencijacije prvo dolazi do smanjenog izražaja gena pluripotentnosti (OCT4), nakon čega 
slijedi kratkotrajni porast izražaja mezodermalnog markera (brachyury).  Rana faza kardijalne 
diferencijacije je obilježena izražajem nekoliko gena, MESP1, NKX2.5 i ISL1.  Terminalna 
faza kardijalne diferencijacija je obilježena izražajem GATA4, MEF2C, TNNT2, TBX20 i 
MYL7. Ionski kanali SCN5A, CACNA1C, KCNH2, KCNJ2 i KCND3 su uglavnom bili 
izraženi tijekom kasne faze diferencijacije. 
Zaključci: Ova disertacija je ponudila nekoliko dokaza koji podupiru hipotezu da se 
kardiomiociti diferencirani iz ljudskih pluripotentnih matičnih stanica mogu koristiti za 
proučavanje APC-a in vitro.  Ovo uključuje: 1) učinkovitu diferencijaciju velikog broja 
kardiomiocita, 2) kardiomiogenezu koja rekapitulira vremenski obrazac izražaja ključnih gena 
važnih za normalnu srčanu diferencijaciju, 3) diferencijaciju kardiomiocita koji su 
ekscitabilne stanice, koji imaju funkcionalne sarkomere, te mogu izvoditi kontrakcije i 4) 
kompetentne odgovore na APC uz aktivaciju karakterističnih medijatora prekondicioniranja. 
Ključne riječi: ljudske pluripotentne matične stanice, diferencijacija, kardiomiociti, 
anesteticima-potaknuto prekondicioniranje, slobodni radikali kisika, mitohondrijska 
permeabilizacijsko-tranzicijska pora. 
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